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The tyrosine kinase receptor Vascular Endothelial Growth Factor 
Receptor 2 (VEGFR2) is a key regulator of angiogenesis. Activity of the 
receptor in endothelial cells follows interaction with its cognate ligands, 
primarily the members of the VEGF family, and involves phosphorylation 
of various tyrosine residues in the intracytoplasmic portion of the 
receptor. By combining biochemical and proteomics studies, here we 
provide the first evidence that membrane-associated VEGFR2 is 
acetylated in endothelial cells at four lysine residues forming a dense 
cluster in the kinase insert domain, and in a single lysine located in the 
receptor activation loop. These modifications are under the dynamic 
control of the acetyltransferase p300 and the two deacetylases HDAC5 
and HDAC6. We demonstrate that VEGFR2 acetylation essentially 
regulates receptor phosphorylation. In particular, VEGFR2 acetylation 
counteracts the process of receptor desensitization following VEGF 
stimulation, still allowing receptor phosphorylation and intracellular 
signaling upon prolonged ligand treatment. Cells expressing VEGFR2 
mutants that cannot be acetylated display reduced levels of receptor 
phosphorylation and impaired migratory capacity. Consistent with these 
findings, molecular dynamics simulations indicated that acetylation of 
the lysine in the activation loop contributes to the transition to an open 
active state, in which tyrosine phosphorylation is favored by better 
exposure of the kinase target residues. Taken together, these findings 
indicate that post-translational modification by acetylation is a critical 










Protein post-translational modifications 
The sequencing of the human chromosomes, achieved in the past 
decade, has revealed that the human genome comprises between 
20,000 and 25,000 genes, a number surprisingly lower in respect to all 
the previous predictions (HumanGenomeSequencingConsortium, 2004). 
Being a number unexpectedly close to that of the simple roundworm C. 
elegans, which has about 20,000 genes, the real complexity of organisms 
seems to reside within proteome rather than in the coding DNA. 
Accordingly, the human proteome has been estimated to encompass 
over 1 million proteins, supporting the notion that single genes encodes 
for multiple proteins (Jensen, 2004). The diversification can be initially 
built at the mRNA level, since several mRNA transcripts may be 
generated through different mechanisms, including transcription 
initiation at alternative promoters, differential transcription termination 
and alternative splicing (Ayoubi & Van De Ven, 1996). In addition, 
proteins might be processed post-translationally in various ways, both 
chemically and structurally, thus resulting in a remarkable increase in 
the diversity and heterogeneity of gene products. More than 300 types 
of protein post translational modifications (PTMs) have been identified 
so far, the vast majority of which are known to be mediated by enzymatic 
activity (Beltrao et al, 2012; Choudhary & Mann, 2010; Walsh, 2006). 
Shortly after translation newly synthetized proteins are subject to stable 
modifications, such as disulphite formation, lipidation, biotynilation and 
lipoylation, which are necessary for the maturation and proper protein 
folding. Conversely, the functional complexity of the proteome is 
dictated by reversible PTMs, which consist in the transient and covalent 
addition of functional groups to the side chain of protein residues, 




Figure 1.1. Multisite protein PTMs. The side chain of aminoacidic residue can 
be modified by several covalent modifications. Some prominent PTMs are 
reported, occurring on a) serine (S) and threonine (T), b) tyrosine (Y), c) aspartate 
(D) and glutamate (E) and d-e) lysine (Lys). Adapted from Yang, Oncogene 2005 
 
Prominent PTMs are phosphorylation on tyrosine, serine, and threonine; 
proline isomerization; lysine ubiquitination, sumoylation, acetylation 
and neddylation; methylation on lysine and arginine residues. One single 
PTM can exert its effect by regulating protein activity as well as turnover, 
structure, intracellular localization and interaction with other 
















mechanisms. More importantly, since many proteins can be modified at 
multiple sites, increasing evidence indicates that a crosstalk among PTMs 
exists, which can be considered as a “protein modification code”, 
according to which PTMs act combinatorially, resulting in a significant 
increase in information content (Hunter, 2007; Yang & Seto, 2008a).  
Inevitably, to make the cellular interaction networks more intelligible, 
there is an urgent need to unravel PTM biological functions and 
decipher how distinct PTMs coordinates each other. 
 
Protein acetylation 
Protein acetylation is a common term used to identify two deeply 
different processes: protein N-terminal acetylation, Nα-terminal 
acetylation or Nt-acetylation, and protein lysine acetylation, Nε-
acetylation or Lys-acetylation. 
The former refers to one of the most widespread chemical modification 
of eukaryotic proteins, consisting in the transfer of an acetyl group 
(CH3CO) from acetyl coenzyme A  (AcetylCoA) to the α-aminogroup of 
the first aminoacid of nascent polipeptides. The reaction is irreversible 
and occurs co-translationally, catalyzed by N-terminal acetyltransferases 
(NATs) associated with ribosome (Gautschi et al, 2003; Polevoda et al, 
2008). Despite it occurs on approximately 80-90% of human proteins and 
50-70% of yeast proteins (Arnesen et al, 2009), little is known about its 
general biological implications and some hypothesis might only be 
derived from data of a handful of cases, highlighting a possible role in 
protein stability and membrane targeting (Arnesen, 2011; Behnia et al, 
2004; Scott et al, 2011). 
On the contrary, protein lysine acetylation is a post-translational and 
extremely dynamic process, which consists in the addition of the acetyl 
moiety to the ε-amino group of lysine residues, using acetylCoA as donor. 
By masking the positive charge of the lysine side chain and impairing its 
ability to form hydrogen bonds, the modification has a significant 
influence on the electrostatic properties of the protein and therefore on 
the regulation of protein function itself (Hodawadekar & Marmorstein, 
2007).  As a reversible process, a water molecule might be used to 
regenerate the lysine amino group by removing the acetyl group and 
releasing an acetate molecule. Moreover, although the vast majority of 
acetylated proteins have been studied in eukaryotic cells, considerable 
evidence of lysine acetylation has been found also in archea and bacteria 
(Bell et al, 2002; Soufi et al, 2012). 
                        
 
 
Figure 1.2. Protein lysine acetylation. Reversible acetylation of a lysine (Lys) 
residue, consisting in the transfer of an acetyl group from acetyl CoA to the e-
amino group of the lysine residue. Adapted from Yang, Oncogene 2007 
 
The first proteins that have been reported as acetylated were histones in 
the early 1960’s (Allfrey et al, 1964; Gershey et al, 1968; Phillips, 1963; 
Vidali et al, 1968). Since the beginning, lysine acetylation was proposed 
as a mechanism of gene expression regulation; in fact, by neutralizing 
histone charge, it allows chromatin structure relaxation and therefore 
makes easier access to nuclear factors, such as the transcription complex 
(Turner, 2000).  Fifteen years later, two non-histone proteins, HMG1 
(high-mobility group protein 1) and α–tubulin, were found acetylated 
(L'Hernault & Rosenbaum, 1985; Piperno & Fuller, 1985; Sterner et al, 
1979); afterwards, p53 and others transcription factors were reported to 
be controlled by HATs activity, thus confirming the notion that 
acetylation is not exclusive for nuclear histones (Gu & Roeder, 1997). 
Since then, the field has experienced an exponential growth and a 
plethora of proteins have been shown to be acetylated by biochemical 
techniques in one or more residues, referring to eukaryotic as well as 
viral and bacterial proteins (Glozak et al, 2005; Sadoul et al, 2010). In 
particular, among prominent PTMs, lysine acetylation has emerged in 
the last decade as a crucial modification which could rival 
phosphorylation in regulating several cytoplasmic processes by 
targeting non-histone proteins and giving rise to complex regulatory 
programs in synergy with other PTMs (Matthias et al, 2008; Spange et al, 
2009; Xiong & Guan, 2012).  
 
The acetylome 
Acetylation is nowadays considered one of the major post-translational 
modifications, which can modulate protein-protein interactions, as well 
as protein stability, activity and localization. Importantly, in the last few 
years, the remarkable advances in mass spectrometry have established 
the ubiquitous nature of protein acetylation by identifying thousands of 
putative acetylated proteins. The first study aimed at determining the 
extent of acetylation at the whole-proteome level in 2006 uncovered 
the acetylation of 195 proteins, of which more that 20% were resident in 
the mitochondria. Moreover, besides the well-defined modification of 
histones and transcription factors, many other acetylation sites were 
found in cytoskeletal proteins as well as in splicing factors, chaperones 
and signaling proteins (Kim et al, 2006). Three years later, an even more 
in-depth view of the in vivo acetylome were accomplished through a 
more sophisticated high-resolution mass spectrometry screening 
(Choudhary et al, 2009). This elegant study reported about 3600 
acetylation sites on 1750 proteins, involved in all major cellular 
processes. Hence, it now appears that the acetylome size is highly 
comparable to that of the phosphoproteome, with a large array of 
proteins displaying exclusive cytoplasmic localization. Intringuingly, 
there was a preference for components of large macromolecular 
complexes, suggesting protein acetylation as an important event in the 
regulation of the multiprotein machinery. Moreover, an account was 
given of the differences in acetylation events following treatment with 
two deacetylase inhibitors (KDACi), SAHA and MS-275. More recently, a 
mass spectrometry analysis from 16 different rat tissues contributed to a 
2-fold expansion of the available acetylome, and a 4-fold extension of the 
acetylation sites. Even more striking was the finding that the patterns of 
protein acetylation are unexpectedly different across tissues; in 
particular, the subcellular distribution of acetylated proteins appears to 
be tissue specific (Lundby et al, 2012). 
A forthcoming interesting frontier in this field of research would be the 
investigation of potential changes in tissue acetylation patterns during 
disease progression, such as cancer, and the uncovering of the 
underlying molecular mechanism of KDACi function, possibly towards 
the development of therapies for various disorders (Haberland et al, 
2009; Kazantsev & Thompson, 2008). 
 
KATs and KDACs 
Protein acetylation is dynamically controlled by two different types of 
enzymes, commonly known as histone acetyltransferases (HATs), which 
add the acetyl moiety on the ε-aminogroup of lysines, and histone 
deacetylases (HDACs), which, conversely, remove the acetyl group 
(Haigis & Guarente, 2006; Lee & Workman, 2007; Yang & Seto, 2008b). 
Since both enzymes display broad activity towards non-histone 
substrate, more general terms have recently been adopted to refer to 
these enzymes; protein lysine acetyltransferases (KATs) and protein 
lysine deacetylases (KDACs) respectively (Allis et al, 2007). It is 
noteworthy that single protein can be substrates for multiple KATs, as 
well as KDACs, which mainly act as catalytic components of distinct 
multiprotein complexes, typically more active than the catalytic 
subunits alone (Lee & Workman, 2007). Thus, most non-catalytic 
interacting partners can bridge the interaction between enzyme and 
substrate and regulate acetyltransferase activity in several ways 
(Berndsen & Denu, 2008). Many KATs contain specific protein modules, 
termed bromodomains, which are able to recognize and bind the 
docking sites created by lysine acetylation (Mujtaba et al, 2007). Besides 
being a pivotal feature in the regulation of chromatin structure and 
transcription by modulating KATs and histones interactions, 
bromodomains can trigger the physical association also between 
acetyltransferases and non-histone substrates, as it happens in the case of 
p53, Tat and MyoD (Bres et al, 2002; Dorr et al, 2002; Mujtaba et al, 2002; 
Mujtaba et al, 2004; Polesskaya et al, 2001). 
In contrast, there are no obvious consensus motifs in the target 
substrates recognized by KATs prior to acetylation. Computational 
analysis of the lysine acetylation sites discovered so far, however, has 
allowed the identification of some common features of the target 
sequences, by which there are some residue preferences at particular 
positions in the proximity of the lysines subject to acetylation. For 
instance, the position -1 relative to the acetylated residue is often 
occupied by glycine residue while in position -2 and +1 reside more 
frequently aromatic residues, such as phenylalanine, tyrosine and 
proline. For the most part, acetylation appears to occur in regions with 
an ordered secondary structure; there is a broad preference for lysine-
rich regions containing phosphorylatable residues (serine and 
threonine), with a particular predilection for negative charge residues in 
the immediate surroundings of the modified site (Basu et al, 2009; Gnad 
et al, 2010; Schwartz et al, 2009). The consensus acetylation sites so far 
identified differ depending on the subcellular compartment in which 
the acetylated protein resides, thus supporting the hypothesis of the 
existence of distinct KATs among subcellular organelles (Choudhary et al, 
2009; Kim et al, 2006; Lundby et al, 2012). In this regard, cluster analysis 
of the acetylation sites identified in a proteomic survey of mitochondrial 
acetyl-proteome has distinguished three distinct classes differentially 
regulated under calorie restriction, of which only one responds 
dynamically to the deacetylase activity of SIRT3. Consistent with the 
previous notion, such a difference could be due to the peculiar 
characteristic in the amino acid sequence and secondary structure of the 
surrounding sequence displayed by each class (Hebert et al, 2013). 
 
KATs 
Since the first histone acetyltransferase was discovered in 
Saccharomyces cerevisiae (HAT1) (Kleff et al, 1995), over 30 other 
proteins, mainly transcriptional co-activators, were shown to possess HAT 
activity. Although KATs are evolutionary conserved from yeast to 
humans, they display a large diversity both in structure and function 
(Yang, 2004) and in substrates recognition, the last largely depending on 
the subunit composition of the multiple subunits complex they belong 
(Kimura et al, 2005; Waterborg, 2002). The historical classification divides 
these enzymes into two categories, type A KATs, located in the nucleus, 
and type B KATs, located in the cytoplasm (Brownell & Allis, 1996). While 
type A KATs are linked to transcription by exerting their enzymatic 
activity on nucleosomal histones within chromatin (Grant & Berger, 
1999), the cytoplasmic B-type KATs catalyze acetylation of newly 
synthetized histones, promoting their transport into the nucleus (Allis et 
al, 1985; Ruiz-Carrillo et al, 1975). Since many KATs have been shown to 
operate in different cellular compartments, a much more accurate 
classification could be made according to sequence similarity and 
conservation of structural motifs, identifying five different groups: the 
general control non-derepressible 5-related N-acetylatransferases 
(GNAT superfamily), the p300/CBP family, the MYST proteins, the basal 
transcription factors and the nuclear receptor cofactors (Roth et al, 2001; 
Sterner & Berger, 2000). The HAT domain sequence is dissimilar between 
families, a divergence meaning that these proteins have evolved for 
more distinct functions rather than just histone acetylation 
(Marmorstein, 2001). 
The GNAT superfamily comprises GCN5 (general control non 
derepressible-5), P/CAF (p300/CREB-binding protein-associated factor) 
and other related proteins, such as HAT1, Elp3 and Med5. Both human 
GCN5 and P/CAF possess a HAT domain, a bromodomain and a specific N-
terminal domain, which is critical in the recognition of chromatin 
substrates (Xu et al, 1998). Their activity is highly conserved among 
species; besides being crucial for transcriptional activation 
(Georgakopoulos & Thireos, 1992; Wang et al, 1997), they have been 
shown to catalyze the acetylation of non-histone proteins as well (Gupta 
et al, 2008; Paolinelli et al, 2009; Sabo et al, 2008). Elp3 is the catalytic 
subunit of the Elongator, a multiprotein complex engaged in 
transcriptional elongation (Svejstrup, 2007). Apart from possessing 
obvious ability in acetylating the histone core, this KAT has been shown 
to be critical in the control of tubulin acetylation (Creppe et al, 2009). 
HAT1 has a pivotal role in chromatin assembly (Parthun, 2007), while 
Med5, which is a component of the Mediator complex, is involved in the 
control of telomeric silencing in Saccharomyces cerevisiae (Liu & Myers, 
2012; Zhu et al, 2011). 
CBP (CREB binding protein) and its cognate protein p300 possess several 
conserved domains, among which a HAT domain, a bromodomain and an 
acetyl-CoA binding domain or Motif A, also shared with MYST proteins 
(Ogryzko et al, 1996). These are the most intensively studied and 
characterized nuclear HATs, able to acetylate both histone and non-
histones protein and to interact with a variety of other factors, a large 
interactome counting more that 400 partners (Bedford et al, 2010; 
Cereseto et al, 2005; Gu & Roeder, 1997). Both CBP and p300 are found in 
mammals, whereas only CBP exists in Drosophila and in Caenorhabditis 
Elegans (Goodman & Smolik, 2000). 
The acronym of the MYST family derives from the four founding 
members: human MOZ, yeast Ybf2, yeast Sas2 and the mammalian Tip60. 
In human the family comprises three additional members, namely MORF, 
HBO1 and MOF. Both the eukaryotic enzymes and the composition of the 
multisubunit protein complexes through which they function are 
extremely conserved in evolution. They are involved in a wide range of 
cellular regulatory functions, including transcription, DNA replication 
and DNA damage response and have been associated with several human 
diseases, among which cancer (Avvakumov & Cote, 2007; Yang, 2004). 
 
KDACs 
The first proof of histone deacetylase activity date back to 1960s  (Inoue 
& Fujimoto, 1969), just a few years after the discovery of histone 
acetylation, introducing immediately the concept of high dynamicity in 
lysine residue modification.  
According to cofactor requirement and mechanism of catalysis used, the 
KDAC superfamily is divided into two distinct families: the “classical 
family” or HDACs, the members of which are structurally related to the 
yeast Hda1/Rpd3 proteins (de Ruijter et al, 2003), and the silent 
information regulator 2 (Sir2)-related proteins or sirtuins (Haigis & 
Guarente, 2006).  
                    
 
 
Figure 1.3.  Mechanisms of lysine acetylation and deacetylation. KAT 
catalyzes the transfer of an acetyl moiety to the side amino group of lysine. 
Conversely, with the involvement of a water molecule, KDAC class I, II and IV 
remove the acetyl group from lysine and release acetate, whereas sirtuins utilizes 
NAD+ as a coenzyme and generate O-acetyl-ADP-ribose and nicotinamide. 
Adapted from Xing, Trends in Plant Science 2005 
 
The members of the classical family possess a high degree of homology in 
the catalytic domain and deacetylate substrates by hydrolysing the 
amide bond with water, relying on an electrophillic divalent zinc cation 
(Hodawadekar & Marmorstein, 2007); on the other side, sirtuins need the 
oxidized form of nicotinamide adenine dinucleotide (NAD+) as cofactor, 
to which they transfer the acetyl group generating two products, 
nicotinamide and 2’-O-acetyl-ADP-ribose (Denu, 2005).  
Moreover, depending on phylogenetic conservation, lysine deacetylases 
are further grouped into four classes (Gregoretti et al, 2004): class I, II and 
IV, which incorporate all the members of the classical family, and class III, 
or sirtuins, with a catalytic core highly conserved from bacteria to 
humans (Marmorstein, 2004).  
Class I comprises protein orthologues to the yeast Rdp3, namely HDAC1, -
2, -3 and -8, with a simple structure, predominantly consisting of the 
deacetylase domain and short N- and C-terminal extensions. They are 
ubiquitously expressed and mainly localized in the nucleus (Kurdistani & 
Grunstein, 2003; Taunton et al, 1996; Yang & Seto, 2008b). 
Class II are related to yeast HdaI and, according to their structural 
organization, further subdivided into two classes: class IIa (HDAC4, -5, -7, -
9) and class IIb (HDAC-6 and -10). These enzymes are considerably larger 
than class I members, about 1000 residues, and possess multiple 
regulatory region besides the catalytic domain. In particular, multiple 
binding sites for 14-3-3 chaperones are located in the N-terminal region, 
which render these enzymes responsive to nuclear-cytoplasmic 
shuttling (Martin et al, 2007; Vega et al, 2004a; Wang et al, 2008). 
Moreover, in the C-terminal part a nuclear export sequence (NES) is 
found involved in the control of class IIa HDACs nucleocytoplasmic 
distribution (McKinsey et al, 2001). The structure of HDAC6 is more 
specific, with two functional catalytic domains and a C-terminal zinc 
finger; it exerts its activity towards a large number of targets in the 
cytoplasm, the compartment where this enzyme is mainly localized 
(Kovacs et al, 2005; Tang et al, 2007; Zhang et al, 2007). Notably, class IIa 
enzymes have the unique feature of being expressed in a tissue-specific 
manner; HDAC4 is enriched in the brain and in chondrocytes (Bolger & 
Yao, 2005; Vega et al, 2004b); HDAC7 is highly expressed in endothelial 
cells and in thymocytes (Chang et al, 2006; Parra et al, 2007); HDAC5 and 
HDAC9 are particularly abundant in brain, heart and skeletal muscle 
(Chang et al, 2004; Kim et al, 2008a; Mejat et al, 2005). 
 HDAC11 is the solitary member of class IV, which shares sequence 
similarity with both Rpd3 and Hda1 (Gao et al, 2002). Although its 
function is still not fully elucidated, there is much information about its 
expression, enriched in brain, heart, kidney, muscle and testis (Bradbury 
et al, 2005; Liu et al, 2008b; Villagra et al, 2009). 
Finally, the yeast Sir2 is the founding member of the sirtuins family, 
which comprises seven paralogs in mammals, SIRT1 to 7 (Frye, 1999; Frye, 
2000). Since their enzyme activity strongly depends on the ratio 
between NAD+ and NADH, they are considered to serve as energy 
sensors, besides being transcription factors (Imai et al, 2000a; Imai et al, 
2000b). Sirtuins show great variation in both subcellular localization and 
substrate specificity, playing key roles in a plethora of metabolic 
processes (Haigis & Sinclair, 2010; Michishita et al, 2005). SIRT1 is a 
nuclear protein, but it also carries out some cytoplasmic function (Jin et 
al, 2007; Tanno et al, 2007); SIRT2 is a cytoplasmic protein, but shows 
nuclear localization in the G2-M phase transition of the cell cycle (North 
& Verdin, 2007; Vaquero et al, 2006); SIRT6 and SIRT7 are found in the 
nucleus, with SIRT7 highly enriched in the nucleolus (Ford et al, 2006; 
Mostoslavsky et al, 2006). SIRT3, 4 and 5 are primarily located in the 
mitochondria (Huang et al, 2010). 
 
KATs and KDACs regulation by acetylation 
Reminiscent of kinases and phosphatases phosphorylation, several 
acetyltransferases and deacetylases exhibit ability in modulating their 
activity one another.   
The best characterized example is the autoacetylation of p300, 
considered as a key event in the regulation of its enzymatic activity, a 
sort of autoregulatory loop that serves as an activation switch (Thompson 
et al, 2004). The rapid acetylation of p300 occurs by an intermolecular 
mechanism in a charge patch within the intact regulatory loop, 
containing a cluster of 12 acetylation sites (Karanam et al, 2006). Besides 
dramatically enhancing its activity, this sharp modification induces 
structural changes (Arif et al, 2007; Black et al, 2006) and thus may 
facilitate the interaction between p300 and the components of the 
multiprotein complexes in which the enzyme is active (Arif et al, 2007; 
Stiehl et al, 2007). Consistent with this notion, deacetylation of p300 by 
SIRT2 negatively affects its activity (Black et al, 2008). Moreover, both 
HDAC6 and SIRT1 repress p300 activity by mediating its sumoylation 
(Bouras et al, 2005; Girdwood et al, 2003). P/CAF acetylation targets 
lysine residues located within the nuclear localization signal (NLS); this 
modification, which can be catalyzed by both P/CAF itself and p300, 
increases the activity of the enzyme and is required for its nuclear 
localization (Herrera et al, 1997; Santos-Rosa et al, 2003). In support to 
this notion, it has been reported that P/CAF deacetylation by HDAC3 is 
responsible for the cytoplasmic retention of the acetyltransferase 
(Blanco-Garcia et al, 2009; Gregoire et al, 2007). 
Within the MYST family as well, the mechanism of autoacetylation has 
been shown to regulate the catalytic activity of some members, namely 
Tip60 and MOF (Peng et al, 2012; Wang & Chen, 2010); in particular, the 
functioning of both enzymes is negatively regulated by SIRT1-
dependent deacetylation (Yang et al, 2012a; Yang et al, 2012b). 
In contrast, KDACs are negatively regulated by acetylation. As reported 
in several independent studies, p300 is responsible for the acetylation of 
HDAC1 as well as HDAC6 and SIRT2, thus leading to a strong attenuation 
of their deacetylase activity (Han et al, 2009; Han et al, 2008; Luo et al, 
2009; Qiu et al, 2006).  
 
Protein acetylation in the regulation of cellular metabolism 
A growing body of evidence sustains an important link between protein 
acetylation and the control of cellular metabolism, according to which 
the concentration of metabolic fuels influence the rate of protein 
acetylation, especially metabolic enzymes, which in turn dictates the 
proper metabolic strategy in response to rapid environmental changes. 
The activity of KATs strongly relies on the availability of Acetyl-CoA, a 
crucial intermediate of many metabolic reactions, which is also the 
source for the acetyl groups transferred to the epsilon aminogroups of 
proteins. In mammalian cells, the enzyme Acetyl-CoA synthetase 2 is 
responsible for the production of the mitochondrial pool of this 
metabolite, while the nuclear and cytoplasmic pools is catalyzed by two 
different enzymes, ATP-citrate lyase (ACL) and Acetyl-CoA synthetase 1 
(AceCS1). ACL generates Acetyl-CoA from mitochondria-derived citrate, 
while AceCS1 from acetate (Hallows et al, 2006; Hatzivassiliou et al, 
2005). The activity of ACL is predominant upon glucose abundance, the 
main carbon source for citrate production under glycolytic conditions. 
Strikingly, it has been recently shown that histone acetylation is 
nutrient-sensitive in both human glycolytic cancer cells and adipocytes, 
since it increases according to glucose uptake through an ACL-
dependent pathway, thereafter affecting the expression of genes 
involved in glucose metabolism (Wellen et al, 2009). The yeast homolog 
to ACL, Acs2p, was correlated to the regulation of histone acetylation as 
well (Takahashi et al, 2006).  Accordingly, in yeast KATs activity is favored 
in nutrient-rich environments, probably due to a higher amount of 
Acetyl-CoA in respect to coenzyme A (CoA) (Friis et al, 2009; Gao et al, 
2007), the ratio of which has additionally been shown to fluctuate during 
metabolic cycle (Tu et al, 2007). 
By contrast, Sirtuin-dependent deacetylation regulates the activity of 
both AceCS1 and AceCS2 (Hallows et al, 2006; Schwer et al, 2006), thus 
coordinating the production of Acetyl-CoA under low nutrient 
conditions. As a matter of fact, it is broadly established that the ratio of 
NAD+/NADH influences the activity of Sirtuins, which are mainly 
functioning under nutrient deprivation, when the concentration of their 
essential cofactor NAD+ is higher (Denu, 2005; Haigis & Sinclair, 2010; 
Imai et al, 2000a). Consistent with this notion, many studies have 
reported that SIRT1 activity is higher during energy limitation than 
under glucose excess (Boily et al, 2008; Chen et al, 2005a; Imai & 
Guarente, 2010). A pivotal substrate of SIRT1 is the peroxisome 
proliferator-activated receptor-γ co- activator 1α (PGC1α), the activity of 
which is turned off by GCN5-mediated acetylation; SIRT1 promotes the 
adaptation to fasting by deacetylating this transcriptional coactivator 
and thus regulating the expression of metabolic genes involved in both 
gluconeogenesis and glycolysis (Lerin et al, 2006; Rodgers et al, 2005).  
Similarly, transcriptional profiling in yeast demonstrates a strong 
correlation between Gcn5 activity and several genes associated with 
different metabolic processes (Johnsson et al, 2006). 
The regulation of cellular metabolism by acetylation occurs also at the 
protein level; of note, almost all enzymes involved in the catalysis of 
intermediate metabolism are post translationally modified, and, more 
importantly, their acetylation status could be reprogrammed in 
response to diet changes in a tissue specific manner (Kim et al, 2006; 
Schwer et al, 2009; Wang et al, 2010; Xiong & Guan, 2012; Zhao et al, 
2010), besides being surprisingly connected also to the circadian clock 
(Masri et al, 2013).  In particular, the mitochondrial protein acetylome is 
primarily controlled by SIRT3, which can sense calorie restriction and 
activate the adaptation response through direct deacetylation of 
metabolic enzymes involved in oxidative metabolism (Hirschey et al, 
2010; Kendrick et al, 2011; Lombard et al, 2007; Someya et al, 2010). 
 
How does lysine acetylation exert its effect? 
The protonation occurring at physiological pH provides lysine side chain 
with a positive charge, frequently exploited by proteins to interact with 
negatively charged targets.  As in the case of histones, lysine acetylation 
weakens their association with the negatively charged DNA molecule, 
resulting in nucleosome remodeling and higher accessibility of DNA to 
the transcription machinery (Brownell et al, 1996; Garcia-Ramirez et al, 
1995; Shogren-Knaak et al, 2006; Wang et al, 2001). Similarly, acetylation 
of transcription factors, such as FoxO (Matsuzaki et al, 2005a), Yin Yang 1 
(YY1) (Yao et al, 2001), High mobility group protein A1 (HMG-A1) (Munshi 
et al, 1998), reduces their DNA-binding capability even if, in most cases, 
transcription factors acetylation enhances their ability to bind DNA 
(Chen et al, 2001). For instance, P/CAF dependent acetylation of E2F-1 
results in an enhanced DNA-binding and transactivation ability 
(Martinez-Balbas et al, 2000; Marzio et al, 2000).  
Resembling this mechanism, protein-protein interactions might also be 
affected by acetylation-induced conformational changes. This is the case 
of proteins containing the aforementioned bromodomains, able to 
recognize the docking sites generated by lysine acetylation and 
promote protein association (Mujtaba et al, 2007), and it is true also for 
proteins that do not contains such a particular module, such as 
transcription factor TFIIB, where acetylation stabilizes the interaction 
with transcription factor TFIIF (Choi et al, 2003), or Stat1, which is able to 
associate with NF-kB p65 only if acetylated (Kramer et al, 2006). On the 
contrary, protein-protein interactions could be disrupted following 
acetylation, as in the case of Nuclear Hormone Receptor Interacting 
Protein (RIP) 140 and transcriptional Co-repressor CtBP, the association 
of which is abolished following RIP140 acetylation (Vo et al, 2001); 
likewise, the acetylated form of the DNA-end joining protein Ku70 loose 
the ability to bind the proapoptotic factor Bax, as well as p53 acetylation 
causes its dissociation from Ku70 (Cohen et al, 2004; Yamaguchi et al, 
2009). 
 
Figure 1.4. Control of protein stability following lysine acetylation.  A) 
Same site-competition, the lysine is acceptor of both acetylation and 
ubiquitination. Acetylation stabilizes protein by preventing their ubiquitination. 
B-C) By regulating complex formation, acetylation might create binding site for 
E3-containing complexes, leading to protein ubiquitination (B) or, in contrast, 
causing complex dissociation and render components accessible for component 
















































In addition to acetylation, the lysine side chain can be target of several 
modifications which could happen simultaneously in a mutually 
exclusive manner, meaning that a specific modification can prevent 
further modifications by others and vice versa. One good example is the 
interplay between protein acetylation and ubiquitination in the control 
of target protein stability. The major mechanism through which this 
regulation occurs is the protection exerted by lysine acetylation that 
impedes protein degradation by means of direct competition with 
ubiquitination. Several crucial regulatory factors have been already 
shown to undergo stabilizing lysine acetylation, such as the oncoprotein 
c-Myc (Vervoorts et al, 2003), the nuclear protein Smad7 (Gronroos et al, 
2002), the transcription factor Runx3 (Jin et al, 2004), the multi-
functional protein WRN (Li et al, 2010), the sphingosine kinase SPHK1 (Yu 
et al, 2012). In contrast, it has been shown that, in some cases, protein 
acetylation is unexpectedly capable of increasing the rate of protein 
degradation by presumably modulating protein-protein interaction.  As 
a matter of fact, the association between Hypoxia-inducible factor 1 
(HIF1α) and von Hippel-Lindau tumor suppressor gene product (pVHL) is 
enhanced following HIF1α acetylation by ARD1, thus favoring HIF1α 
ubiquitination and subsequent proteasomal degradation (Jeong et al, 
2002). In a similar fashion, acetylation stimulates the interaction 
between phosphoenolpyruvate carboxykinase (PEPCK1) and the E3 
ubiquitin ligase URB5, again prompting ubiquitination and proteasomal 
degradation (Jiang et al, 2011; Zhao et al, 2010). Acetylation leads to 
protein destabilization also in the case of the retinoblastoma tumor 
suppressor protein RB, targeted for proteasomal degradation 
subsequent to Tip60-mediated acetylation (Leduc et al, 2006). Another 
indirect way for lysine acetylation to stimulate protein degradation is 
the control of HSP90 chaperone activity (Bali et al, 2005; Scroggins et al, 
2007), altering HSP90 ability to interface client proteins, such as HIF1α 
and glucocorticoid receptor (Kong et al, 2006a; Kovacs et al, 2005). 
Alternatively, lysine acetylation might mingle with other PTMs directed 
on neighboring residues, either hindering or favoring secondary 
modifications. Recent studies reiterate the reciprocal regulation 
between phosphorylation and acetylation occurring on different 
residues, either adjacent or far away, which in turn affect each other in 
response to external signals (as depicted in cartoon 1.5).  
 
Figure 1.5. Crosstalk between phosphorylation and acetylation. Acetylation 
can regulate phosphorylation on serine (S), threonine (T), or tyrosine (Y), and vice 
versa. The lysine can be either N-terminal or C-terminal from the phosphorylation 
site. Adapted from Yang, Molecular cell 2008 
 
Acetylation enhances the interaction between glycogen phosphorylase 
(GP), a key enzyme in the glucose metabolism, and protein phosphatase 
1 (PP1), thereby inducing the enzyme dephosphorylation with a 









same way, phosphorylation of Akt is prevented when the kinase is 
acetylated at two residues located in the pleckstrin homology domains, 
which mediate phosphatidylinositol 3,4,5- trisphosphate (PIP3) binding 
(Sundaresan et al, 2011). A counteraction was demonstrated between 
phosphorylation and acetylation also in the case of STAT1, since the T-cell 
protein tyrosine phosphatase (TCP45) binds specifically to the acetylated 
transcription factor, catalyzing its dephosphorylation and thereby 
blocking its activity (Kramer et al, 2009). RB acetylation also hampers its 
phosphorylation, thus leading to cell cycle arrest (Nguyen et al, 2004). 
Acetylation may have a broad role in the regulation of cyclin dependent 
kinase (CDK) function, as the modification of highly conserved residues in 
the catalytic core of both CDK2 and CDK9 inhibits enzyme kinase activity 
(Mateo et al, 2009; Sabo et al, 2008). 
On the contrary, acetylation might favor phosphorylation, as it happens 
in the case of GCN5-mediated acetylation of the cell-division cycle (CDC)-
6 protein, which is essential for the subsequent phosphorylation and 
activation of the enzyme (Paolinelli et al, 2009). Similarly, transcription 
factors FOXO1 is translocated from the nucleus to the cytoplasm in 
response to Akt-mediated phosphorylation, which is, in turn, induced by 
FOXO1 acetylation (Matsuzaki et al, 2005b). 
 
Acetylation and the function of specific non-histone proteins 
To illustrate the complexity of some of the molecular programs 
previously described, this section reports a few representative examples 
of the crosstalk between acetylation and others PTMs in non-histonic 
proteins. 
p53 
The best example of crosstalk among PTMs in the control of protein 
function is represented by the well-refined and tight post-translational 
modulation of the activity of the tumor suppressor p53. Considered as 
“the guardian of the genome”, this transcription factor has an undisputed 
and pivotal role in gene expression regulation in response to a variety of 
stimuli (Beckerman & Prives, 2010; Vousden & Lane, 2007). More than 36 
amino acids within p53 undergo different modifications, with 
phosphorylation, ubiquitination and acetylation having the major impact 
on such a complex regulatory network (Kruse & Gu, 2009). The levels of 
p53 acetylation are particularly elevated in response to a variety of 
stress-inducing stimuli. In particular, CBP/p300 is responsible for the in 
vivo acetylation of five lysines located in the p53 C-terminal region of 
p53 (Lys370, Lys372, Lys373, Lys381, Lys382) (Gu & Roeder, 1997; Pearson 
et al, 2000). Interestingly, the interaction with p300 is triggered by the 
phosphorylation of serine residues located in the N-terminal region of 
p53 (Sakaguchi et al, 1998), while acetylation of Lys373 induces 
hyperphosphorylation of p53 N-terminal residues (Knights et al, 2006). 
Furthermore, p53 hyperacetylation abrogates Mdm2-mediated 
ubiquitination and degradation, correlating with enhanced activity and 
stability of the transcription factor (Ito et al, 2001; Li et al, 2002). 
Mutually exclusive modifications of Lys320 in the nuclear localization 
signal are under the control of P/CAF and the ubiquitin ligase E4F1, the 
latter being responsible for the induction of a transcriptional program 
involved in cell cycle arrest (Le Cam et al, 2006; Liu et al, 1999). In 
contrast, the cytoplasmic E4 activity exerted by p300/CBP towards p53 
targets it for ubiquitination, thus causing its destabilization (Shi et al, 
2009). Nonetheless, it still remains elusive whether p53 carboxi-terminal 
acetylation has a primary role in the transcriptional activity and stability 
of the protein rather than only fine-tuning the p53-mediated response 
(Feng et al, 2005; Krummel et al, 2005; Yamaguchi et al, 2009). In 
addition to those mentioned above, there are two other important 
lysines lying in the DNA-binding core domain, Lys120 and Lys164, targets 
of hMOF or TIP60, and CBP/p300 respectively. Lys120 specific acetylation 
occurs after DNA damage and is required for p53-driven activation of the 
proapoptotic target genes bax and puma, and serves as a key switch 
between the p53 cell cycle arrest and apoptotic functions (Sykes et al, 
2006; Tang et al, 2006). Unexpectedly, methylation on Lys372 by the 
protein methyltransferase Set7/9 serves as an anchor for TIP60 to exert 
its action on lysine 120 (Kurash et al, 2008). The simultaneous mutation 
at Lys120, Lys164 or the six C-terminal lysines greatly impairs p53 ability 
to activate p21 and suppresses cell cycle progression, while loss of 
acetylation at individual sites can be compensated by modification of the 
other sites, without any significant effect on p21 induction (Tang et al, 
2008).  
The complex regulation of p53 acetylation also comprises the action of 
almost four different KDACs, namely HDAC1, HDAC3, SIRT1 and SIRT7, 
which are fundamental in maintaining the delicate equilibrium between 
p53 acetylation and deacetylation, even though their site specificity is 
not clearly defined yet (Cheng et al, 2003; Luo et al, 2001; Luo et al, 2000; 
Vakhrusheva et al, 2008; Vaziri et al, 2001; Zeng et al, 2006). 
α -tubulin 
Dynamic and proper changes in eukaryotic cytoskeletal organization are 
strictly required during cell division, as well as in carrying out a variety of 
essential functions in cell motility and transport of vesicles through the 
cells. A key component of the cytoskeleton is the microtubules network, 
the building blocks of which are subject to a variety of reversible PTMs 
that influence the interactions with other proteins (Westermann & 
Weber, 2003). Even though the acetylation of α - tubulin on Lys40, a 
residue that points toward the lumen of the microtubule, was 
discovered in mammalian cells almost three decades ago (L'Hernault & 
Rosenbaum, 1985), the responsible acetyltransferase, Elp3, has been 
identified only recently (Creppe et al, 2009). Tubulin acetylation was 
correlated to binding of cargo proteins and therefore to protein 
trafficking and vesicular transport (Dompierre et al, 2007; Reed et al, 
2006). High levels of α-tubulin acetylation are present in stable 
microtubules that, in contrast, result hypo-acetylated during 
cytoskeleton dynamic processes, such as cell migration. In agreement, 
the overexpression of HDAC6 and SIRT2, the most active tubulin 
deacetylases, promotes chemotactic cell movement and counteracts 
oligodendrocyte differentiation respectively (Hubbert et al, 2002; Li et 
al, 2007; Matsuyama et al, 2002; North et al, 2003). HDAC6-deficient mice 
show hyperacetylated tubulin in most tissue, but are fertile and develop 
normally (Zhang et al, 2008).  
Cortactin 
As a filamentous actin-binding protein, cortactin has the ability to 
coordinate membrane dynamics and cytoskeleton remodeling (Wu & 
Parsons, 1993). Cortactin undergoes acetylation in 11 different lysines 
due to P/CAF action, eight of which (Lys87, Lys161, Lys189, Lys198, 
Lys235, Lys272, Lys309, and Lys319) are located in a highly repeated 
region of the protein. The acetylation of one single lysine does not lead 
to significant effects, while the hyperacetylation in nine residues 
prevents the interaction with F-actin and impedes cortactin traslocation 
to the cell periphery, thus causing impairment in cell motility (Zhang et 
al, 2007). Likewise, cortactin has been recently pointed out as a novel 
substrate of both p300 and SIRT1, which cooperate in regulating cell 
motility, similar to P/CAF and HDAC6 (Kaluza et al, 2011; Zhang et al, 
2007; Zhang et al, 2009b).  
Plasma Membrane Receptors 
Acetylation has been recently implicated in the control of 
transmembrane growth factor receptor activity and cytokine-mediated 
signal trasduction. 
The Interferon α (INFα) antiviral response is mainly triggered by type I 
interferon receptor (INFαR) 1 and 2 oligomerization, which in turn 
mediate intracellular activation of STAT1 and -2 proteins (Schindler et al, 
2007). Acetylation is involved in many steps of type I INF signalling 
pathway, as IFNαR2 as well as interferon regulatory factor 9 (IRF9) and the 
activator of transcription STAT2 have been found acetylated in response 
to IFNα. In particular, upon INFα treatment, CBP is exported in the 
cytoplasm, where it interacts with both INFαR2 and IRF9; IFNαR2 
acetylation creates the docking site for IRF9, the acetylation of which, in 
turn, influences dimer formation and DNA binding. STAT1 and STAT2 
interaction is regulated by acetylation as well. Interestingly, the 
crosstalk between lysine acetylation and serine phosphorylation in 
IFNαR2 is required to initiate the IFNα-mediated intracellular signaling 
(Tang et al, 2007).  
The acetylation of the Insulin-like Growth Factor 1 (IGF-1) receptor has 
been detected during a mass spectrometry survey in a conserved 
residue, Lys1088. Lying in a region of high similarity with the Insulin 
receptor, the modification of such residue suggests a more general 
mechanism for kinase activity regulation of transmembrane receptors 
(Choudhary et al, 2009). In support to this notion, the first evidence of 
the functional relevance of acetylation in the regulation of Receptor 
Tyrosine Kinase activity comes from the discovery of Epidermal Growth 
Factor Receptor (EGFR) acetylation by CBP. The receptor modification is 
linked to enhanced phosphorylation and oncogenic potential in tumor 
cell lines, besides being also pivotal for receptor internalization (Goh et 
al, 2010; Song et al, 2011). This recent finding unravels new unexplored 
possibilities to better comprehend the mechanisms controlling 
signaling transduction in response to growth factor stimulation. 
Mechanisms of vessel development 
The formation of an extensive and functional vascular network is 
essential for the proper delivery of oxygen and nutrients to every part of 
the body, besides allowing hematopoietic cells to patrol the organism 
for immune surveillance. The establishment of a highly branched 
vascular tree requires the perfect orchestration of several molecular and 
cellular players which direct both the processes of vasculogenesis and 
angiogenesis, the former occurring through de novo vessel formation 
and the latter through remodeling of preexisting vascular structure 
(Adams & Alitalo, 2007; Carmeliet & Jain, 2011). 
During the early stages of embryogenesis, de novo blood vessels 
formation initiates with the recruitment of mesoderm-derived 
endothelial precursors cells (EPCs, hemangioblast), which differentiate 
and aggregate to form blood islands, as it was already reported at the 
beginning of the 20th century (Choi et al, 1998; Huber et al, 2004; Sabin, 
1917). The subsequent assembly of these islands gives rise to a primitive 
vascular network, known as primary capillary plexus, a honeycomb 
shaped structure from which the dorsal aorta, the cardinal vein and the 
embryonic stems of yolk sac arteries and veins originate (Drake & 
Fleming, 2000; Ferguson et al, 2005). This immature vasculature then 
expands and undergoes remodeling via sprouting, branching, pruning 
and intussusceptive growth of preexisting capillaries, until a 
hierarchically complex vascular organization is eventually obtained, 
possessing all the different hemodynamic properties that enable 
transportation of blood throughout the organism (Adams & Alitalo, 2007; 
Jain, 2003). For the angiogenic sprouting to occur, some selected 
endothelial cells (EC), called tip cells, take the lead and guide the new 
sprout towards a gradient of proangiogenic factors, such as that formed 
by the Vascular Endothelial Growth Factor A (VEGF-A). Behind the tip, the 
stalk cells are intended to support the sprout elongation by proliferating 
and forming the vascular lumen. The Notch pathway controls the 
specification of EC into tip and stalk cell (Eilken & Adams, 2010; Phng & 
Gerhardt, 2009; Potente et al, 2011).  
 
 
Figure 1.6. Blood vessel development. A) During the process of 
vasculogenesis, EC progenitors assemble a primitive vascular network, which is 
then remodeled until the stabilized and mature vessel network are formed. B) 
Steps of vessel sprouting. Adapted from Potente, Cell 2011 
 
Arteries and veins are then formed through the process of artero-venous 
differentiation, during which they acquire their specific identities 
through the acquisition of specific anatomical and morphological 
composition (Gaengel et al, 2009; Swift & Weinstein, 2009). At the 
molecular level, genetic specification determines the cell types, as 
Vascular Endothelial Growth Factor (VEGF) signaling promotes arterial 
specification upstream of the Notch pathway (Lawson et al, 2001; Lawson 
et al, 2002), whereas the COUP transcription factor II (COUP-TFII) 
regulates differentiation towards the venous phenotype, inhibiting both 
Neuropilin 1 (NP1) and Notch pathways (You et al, 2005). In turn, Notch 
regulates the expression of the best known arteriovenous markers, as it 
triggers the upregulation of the transmembrane ligand Ephrin-B2 in the 
arterial endothelium and suppresses the expression of the cognate 
receptor Ephrin B4, which is, conversely, confined to the venous 
endothelium (Kim et al, 2008b; Lawson et al, 2001). Additionally, blood 
vessel formation requires stabilization, which mainly occurs through 
recruitment of mural cells and generation of extracellular matrix, thus 
forming a basement membrane that keeps vessel structure in shape 
(Gaengel et al, 2009; Jain, 2003). 
In the healthy adult organism, apart from cycling ovary and placenta 
during pregnancy, there is no evidence of active angiogenesis, until 
quiescent vessels are stimulated to respond to inflammatory or hypoxic 
stimuli, as it happens during wound healing. An imbalance of the 
angiogenic stimuli might contribute to several pathologies, both 
towards excessive angiogenesis, such as in tumor growth and 
inflammatory and ocular disorders, or insufficient angiogenesis, as in the 
case of ischemic and peripheral artery disease.  
 
Vascular endothelial growth factors 
Key actors in blood vessel formation are the members of the Vascular 
Endothelial Growth Factor (VEGF) family, which comprises in mammals 
five distinct secreted dimeric glycoproteins of approximately 40 kDa, 
known as VEGF-A, -B, -C, -D and placental growth factor (PlGF). Their 
biological effects are mainly mediated by three tyrosine kinase 
receptors, Vascular Endothelial Growth Factors Receptors 1, -2, -3 
(VEGFR1, VEGFR2 and VEGFR3). In addition, in parapoxvirus a protein 
structurally related to VEGFs, termed VEGF-E (Lyttle et al, 1994), exerts a 
VEGF-A-like activity by specifically binding to and activating VEGFR2 (Kiba 
et al, 2003; Meyer et al, 1999). VEGF homologues, known as svVEGF, have 
also been identified in snake venom (Junqueira de Azevedo et al, 2001; 
Suto et al, 2005), and are exploited by snakes to induce local vascular 
permeability in target animals, preferentially through VEGFR1 activation 
(Takahashi et al, 2004). 
VEGFs share a high structural homology with the members of the 
platelet derived growth factor (PDGF) supergene family, generating 
dimers with intra- and intermolecular disulphide bonds between eight 
conserved cysteine residues. The crystal structure of human VEGF-A 
revealed two monomers organized in an antiparallel fashion and 
covalently linked by disulphide bridges between two conserved 
cysteines, thus defining two receptor-binding sites located at each pole 
of the dimer (Muller et al, 1997). Although VEGFs act predominantly by 
forming homodimers, VEGF-A and PlGF are able to form heterodimers, 
which have been detected in tumors and are able to potentiate VEGF-A 
driven angiogenesis under pathological conditions (Cao et al, 1996; 
Carmeliet et al, 2001; DiSalvo et al, 1995).   
Since VEGFs exert their function regulating pivotal processes on a variety 
of cell types, their bioactivity is strictly regulated at many levels, 
including gene expression, tissue specificity, alternative splicing and 
proteolytic processing.  
VEGF-A 
VEGF-A (also known as VEGF) is the main component of the family and key 
regulator of blood vessel formation. Abnormal blood vessel formation 
and circulatory disfunction are the causes of death at mid-gestation of 
mice lacking even only a single VEGF allele (Carmeliet et al, 1996; Ferrara 
et al, 1996). It is secreted by endothelial cells, as well as macrophages 
and activated T-cells (Freeman et al, 1995; Lee et al, 2007; Melter et al, 
2000) and in adult it is robustly expressed in many tissues, such as brain, 
lung, liver, kidney and heart (Maharaj et al, 2006). Being pivotal in 
vascular maintenance, many stimuli including hypoxia, growth factors 
and nitric oxide (NO) controls VEGF at the transcriptional level (Dor et al, 
2001; Kimura et al, 2002; Ladoux & Frelin, 1993). Moreover, VEGF mRNA 
undergoes alternative splicing that in humans gives rise to at least nine 
isoforms, of which VEGF121, VEGF165 and VEGF189 (VEGF120, VEGF164 and 
VEGF188 in the mouse) are the most abundant. Their distribution is 
determined by the presence of basic amino acidic stretches near the C-
terminus, responsible for the interaction with extracellular matrix 
heparan sulphate proteoglicans (HSPG); thus, the shorter isoform VEGF121 
is completely diffusible, VEGF189 is almost completely localized on the 
cell surface or in the extracellular matrix and VEGF165 is found both as 
soluble and HSPG-bound factor (Giacca, 2010). The VEGF gradient that 
the differential expression of these isoforms create is a powerful tool for 
finely controlling the pattern of growing vessel networks, as it was 
exquisitely demonstrated in tip-stalk cell specification and vessel 
branching (Phng & Gerhardt, 2009; Ruhrberg et al, 2002; Stalmans et al, 
2002). Genetic studies in mice expressing single VEGF isoforms highlight 
the importance and the distinct roles of these molecules in arterial 
development and vascular morphogenesis. It is noteworthy that mice 
expressing only VEGF164 mice are normal and healthy, whereas VEGF120 
mice die perinatally with severe defects in vascular remodeling and 
VEGF188 alone results in abnormal arterial formation and vessel 
branching (Stalmans et al, 2002). In addition, mice lacking VEGF164 and 
VEGF188 show impaired myocardial angiogenesis (Carmeliet et al, 1999b).  
VEGF exerts a direct action also in the prevention of motoneuron 
degeneration (Zacchigna et al, 2008a), in promoting survival and 
regeneration of skeletal muscle (Arsic et al, 2004; Germani et al, 2003), as 
well as in recruiting bone marrow derived cells at the sites of 
neoangiogenensis to promote vessel maturation (Carrer et al, 2012; 
Zacchigna et al, 2008b). 
 
PlGF 
Initially discovered in human placenta (Maglione et al, 1991), PlGF 
transcripts have been detected also in other tissue such as the heart, 
skeletal muscle and lung (Persico et al, 1999). Like VEGF, it undergoes 
differential splicing, giving rise to at least four different isoforms, PlGF-1, 
PlGF-2, PlGF-3 and PlGF-4 (Yang et al, 2003). Different from VEGF, PlGF-
deficient mice are viable and healthy, suggesting that the factor is 
dispensable for embryonic and adult physiological angiogenesis; 
conversely, PlGF contribution is pivotal in various pathologies, such as 
tumor growth, inflammation and ischemia (Carmeliet et al, 2001; Fischer 
et al, 2007; Fischer et al, 2008; Van de Veire et al, 2010). In agreement, 
overexpression of this growth factor was correlated to tumor 
development, including gastric and breast carcinoma (Chen et al, 2004; 
Parr et al, 2005), as well as hepatocellular and renal cancer (Ho et al, 
2007; Matsumoto et al, 2003) and chronic myeloid leukemia (Schmidt et 
al, 2011). In other instances, the PlGF gene was shown epigenetically 
silenced, as it happens in colon and lung carcinoma (Xu & Jain, 2007). 
Consistent with its disease-specific activity, PlGF promotes tumor growth 
(Marcellini et al, 2006; Schmidt et al, 2011; Snuderl et al, 2013), and its 
specific blockage implies both antiangiogenic and antitumor effects 
(Lassen et al, 2012; Marcellini et al, 2006; Schmidt et al, 2011). 
At the cellular level, PlGF is considered a pleiotropic factor, acting on 
various cell types and inducing a variety of biological responses. It is 
capable to stimulate angiogenesis acting as a mitogenic and 
chemoattractant factor for endothelial cells (Adini et al, 2002; Carmeliet 
et al, 2001; Roy et al, 2005; Ziche et al, 1997), besides being able to 
target mural cells as well (Bellik et al, 2005; Yonekura et al, 1999). 
Furthermore, PlGF recruits bone marrow-derived cells that 
consequently release proangiogenic factors, thus suggesting an indirect 
mechanism through which PlGF may induce angiogenic processes 
(Clauss et al, 1996; Hattori et al, 2002; Luttun et al, 2002; Pipp et al, 2003; 
Selvaraj et al, 2003).  Consistently, the loss of PlGF was shown to skew the 
polarization of Tumor Associated Macrophages (TAMs), thus resulting in 
reduction of tumor growth and metastasis (Rolny et al, 2011). 
PlGF-activity is mediated by binding to VEGFR1 and to the co-receptor 
NP1. An anti-PlGF blocking antibody, inhibiting binding to VEGFR1 and 
formation of VEGFR1-NP1 complexes, also inhibited the growth and 
metastasis of various tumors (Fischer et al, 2007), an antitumoral effect 
strongly dependent on the expression of VEGFR1 in tumor cells (Yao et 
al, 2011). The same remarkable effect of PlGF/NP1 blockade in the 
inhibition of tumor progression was also demonstrated in 
medulloblastoma, the most common malignant pediatric brain tumor 
(Snuderl et al, 2013). 
 
VEGF-B 
Two protein isoforms are generated through alternative splicing of the 
VEGF-B gene, VEGF-B167 and VEGF-B186, which give rise to 42 and 60 kDa 
homodimers, respectively. The two isoforms differ at the C-terminus, 
since the longer is diffusible, whereas the shorter exclusively contains a 
heparin-binding domain, which permits anchorage to cell surface and 
extracellular matrix HSPGs (Olofsson et al, 1996a; Olofsson et al, 1996b). 
In addition to VEGFR1 (Olofsson et al, 1998), both VEGF-B167 and VEGF-B186 
also bind NP1 (Makinen et al, 1999), expressed on endothelial as well as 
on other cell types. Accordingly, VEGF-B has a wide tissue distribution, 
even if it is prominently expressed in the adult myocardium and skeletal 
muscle (Lagercrantz et al, 1998; Li et al, 2001; Olofsson et al, 1996a). 
The VEGF-B knock out mouse develops normally. Instead, upon stress, 
VEGF-B deficiency results in altered heart size and atrial conduction 
abnormalities (Aase et al, 2001; Bellomo et al, 2000). Other studies have 
suggested that VEGF-B exerts proangiogenic activity under pathological 
conditions, most likely acting as a survival factor for vascular cells (Zhang 
et al, 2009a). Interestingly, unlike VEGF-A, this factor display a restricted 
role in angiogenesis (Li et al, 2008a), with particular high efficiency in 
the ischemic heart, as its delivery in the infarcted myocardium 
significantly increases angiogenesis and arteriogenesis (Lahteenvuo et 
al, 2009; Li et al, 2008a). VEGF-B167 has a direct role in cardiomyocyte 
survival as well, either by exerting an antiapoptotic effect (Pepe et al, 
2010; Zentilin et al, 2010) or by regulating lipid metabolism (Karpanen 
et al, 2008). In particular, its role in energy metabolism was also 
confirmed in endothelial cells, where it regulates fatty acid uptake, thus 
implying obvious important implications of VEFG-B functioning in organs 
with high metabolic stress, such as the heart (Hagberg et al, 2010). The 
potent antiapoptotic effect that VEGF-B167 exerts through activation of 
VEGFR1 was also demonstrated in neurons of both retina and brain (Li et 
al, 2008b). Similarly, VEGF-B186 was reported to be a neuroprotective 
factor, which drives cell survival in different types of neurons, such as 
motor, sensory and dopaminergic neurons (Dhondt et al, 2011; Falk et al, 
2009; Poesen et al, 2008). 
 
VEGF-C and VEGF-D 
Dissimilarly from other VEGF members, both VEGF-C and VEGF–D are 
produced as a preprotein with unique N- and C- terminal extensions, 
which undergo proteolytic processing (Joukov et al, 1996; McColl et al, 
2003; Yamada et al, 1997). Interestingly, the affinity for their cognate 
receptors is increased upon their proteolitic cleavage (Joukov et al, 
1997; Leppanen et al, 2011; Stacker et al, 1999). They bind and activate 
both VEGFR3 and VEGFR2, and in addition, VEGF-C binds Neuropilin 2 
(NP2) (Joukov et al, 1996; Xu et al, 2010). By activating VEGFR3, both 
growth factors are able to induce lymphatic endothelial cell growth and 
migration (Makinen et al, 2001). VEGF-C is expressed in the heart, small 
intestine, placenta, ovary and the thyroid gland in adults, whereas VEGF-
D is found particularly in lung, heart, skeletal muscle, and vascular 
endothelium (Roy et al, 2006). VEGF-C is essential for lymphangiogenesis, 
as its deficiency in mice leads to a complete absence of lymph vessels 
and embryonic lethality, whereas blood vasculature grows normally 
(Karkkainen et al, 2004). In agreement, transgenic expression of VEGF-C 
induces lymphangiogenesis (Jeltsch et al, 1997), and it occurs in an Akt-
dependent manner (Zhou et al, 2010). Unexpectedly, the phenotype of 
the double KO mice for VEGF-C and VEGF-D does not resemble that of 
their cognate receptor KO mice, but mainly results in defects in 
lymphatic vessels without any involvement in embryonic angiogenesis 
(Haiko et al, 2008). Even if VEGF-D is not required for the development of 
the lymphatic system (Baldwin et al, 2005), it induces the formation of 
lymphatics within tumors (Stacker et al, 2001) and it seems to also affect 
tumor angiogenesis (Achen et al, 2001). Moreover, among the VEGF 
family members, VEGF-D is the most potent in inducing both 
angiogenesis and lymphangiogenesis upon gene transfer in skeletal 
muscle (Rissanen et al, 2003). 
The biology of VEGF receptors 
A large series of growth factors and their associated cell-surface receptor 
tyrosine kinase (RTKs) play pivotal roles in controlling the functionality of 
all the major cellular processes during the lifetime. As a matter of fact, 
deregulation of one or more RTKs causes severe pathophysiological 
consequences, including cardiovascular disorders, cancer, inflammation, 
diabetes (Lemmon & Schlessinger, 2010). There are 58 known human 
RTKs, categorized into 20 subfamilies depending on their structure; 
despite the impressive advances that the field has experienced over the 
last 40 years, the sophisticated and complex signaling networks 
activated by RTKs are still not completely puzzled out.  
According to the canonical view, once the ligand intercepts the cognate 
RTK in its inactive state, it induces receptor activation by primarily 
crosslinking two molecules into a dimeric complex. Afterwards, ligand 
binding drives conformational changes in the intracellular domain of the 
receptor, prompting the exposure of the ATP-binding site with 
consequent kinase activation and transfer of a phosphate group to 
tyrosine residues, either on the receptor dimer itself or on downstream 
effectors (Lemmon & Schlessinger, 2010). Despite this model has been 
widely confirmed, it has been recently evidenced that some RTKs, such as 
the epidermal growth factor receptor (EGFR) and the insulin receptor 
(IGF-1R), are able to associate even in the absence of ligand (Clayton et al, 
2005; Gadella & Jovin, 1995; Ward et al, 2007), and that for some others 
(e.g. ephrins receptors and the Tie2 angiopoietin receptor) activation 
depends on the formation of oligomers rather than dimers (Barton et al, 
2006; Himanen & Nikolov, 2003).  
 
 
Figure1.7. Receptor Tyrosine Kinase family. Schematic representation of the 
20 subfamilies of RTKs, with the family members listed beneath. Adapted from 
Lemmon, Cell 2010 
 
As mentioned before, the members of the VEGF family remain the most 
critical regulators of blood vessels formation. The VEGF polypeptides 
bind in an overlapping manner to three RTKs, namely VEGFR1, also called 
fms-like tyrosine kinase 1 (Flt-1) in mouse (de Vries et al, 1992; Shibuya et 
al, 1990), VEGFR2, also known as kinase domain region (KDR) in human or 
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1991), and VEGFR3, also named Flt-4 (Pajusola et al, 1993). To date, VEGF-
A, -B and PlGF bind to VEGFR1, VEGF-A and the proteolytically processed 
VEGF-C and -D bind to VEGFR2 and VEGF-C and -D bind to VEGFR3. 
Proteolytic processing of VEGF-C and -D allows binding to VEGFR2, even 
though with lower affinity compared to VEGFR3 (Koch et al, 2011). Thus, 
depending on which pair of ligand and receptor is involved, a great 
diversity of intracellular signaling cascades may be generated triggering 
various biological outcomes. 
 
 
Figure 1.8. Mammalian VEGF-VEGFR interaction. Schematic representation of 
the interaction of the VEGF family members with their cognate receptors. Adapted 
from Pavlacovic, Ann N Y Acad Sci. 2010 
 
All these three receptors display similar molecular architecture, both in 
the extracellular and cytoplasmic regions. Because of the extracellular 
domain (ECD) organization, VEGFRs are classified as type V RTKs, with 
approximately 750 amino-acid residues organized in seven 
immunoglobulin (Ig)-like loops. The fifth Ig-like domain of VEGFR3 has a 
more peculiar characteristic, showing a disulphide bridge which serves 
as a connection between the proteolytically cleaved N-terminal part of 
the receptor and the rest of the protein (Pajusola et al, 1994). The ECD is 
linked to a single transmembrane portion, followed by the 
juxtamembrane domain, the tyrosine kinase domain and the C-terminal 
tail. Of note, the kinase domain is split into two parts by the insertion of  a 
70 amino acid sequence, defined as the kinase insert domain (KID), an 
unusual feature shared also with the other members of the RTK subclass 
to which they belong, e.g. PDGF receptors and fibroblast growth factor 
(FGF) receptor. 
VEGFRs bind ligands both in cis and in trans. The former type of 
interaction implies that the receptor contacts either the free diffusible 
ligand or the VEGF polypeptide presented by co-receptor lying on the 
same cell; conversely, in the trans interaction the ligand is presented by a 
co-receptor expressed on neighboring cells, further increasing the 
signal amplitude and the communication among adjacent cells 
(Jakobsson et al, 2006; Miao et al, 2000). In addition to homo-dimers, 
VEGF polypeptides may induce the formation of hetero-dimers, 
depending on the availability and binding specificity of the ligands. 
VEGFR1/VEGFR2 interaction might be promoted by VEGF-A, as well as by 
VEGF-A/PlGF hetero-dimers (Autiero et al, 2003; Huang et al, 2001). This 
receptor hetero-dimerization has been predicted by computational 
modeling as unavoidable in cells expressing both receptors, with 
minimal homo-dimerization of the less abundant receptor (Mac Gabhann 
& Popel, 2007). Moreover, the formation of VEGFR1/VEGFR2 hetero-
dimers has been described to contribute to the regulation of EC 
homeostasis, by mainly mediating EC migration, in vitro tube formation 
and vasorelaxation of arterial tissue (Cudmore et al, 2012). VEGFR2 is also 
able to interface with VEGFR3 in response to VEGF-A, -C or –D 
stimulation, and in such cases the phosphorylation pattern of VEGFR3 in 
the homo-dimers substantially differs from the monomer in the hetero-
dimers, which lack the phosphorylation of two C-terminal residues 
(Dixelius et al, 2003). Nevertheless, the association with VEGFR2 seems to 
be required for efficient VEGFR3 phosphorylation (Alam et al, 2004), with 
consequent implications in several cellular responses both in lymphatic 
and blood vessels, such as EC proliferation, angiogenic sprouting, 
lymphatic migration and proliferation (Goldman et al, 2007; Nilsson et al, 
2010; Tvorogov et al, 2010). On the contrary, in EC VEGFR3 could 
decrease the level of phosphorylated VEGFR2, thus functioning as a 
negative modulator for its activity in vascular development (Zhang et al, 
2010). 
Among the VEGFRs, the binding of ligands to the cognate receptor is 
essentially determined by the differential way through which the ECD 
subdomains of each dimer component interact with one another. The 
crystal structure of VEGFR1, either alone or in complex with a ligand, 
exhibits hydrophobic interactions stabilizing the dimers, the formation 
of which mainly occurs through the second Ig-like domain with the 
important contribution of Ig-like domains 1 and 3 (Christinger et al, 
2004; Davis-Smyth et al, 1996; Tanaka et al, 1997). Regarding VEGFR2, 
biochemical analysis demonstrate that subdomains 2 and 3 are required 
for ligand binding (Fuh et al, 1998; Shinkai et al, 1998), while VEGFR3 
binding of the ligand involves Ig-loops 1 and 2 (Jeltsch et al, 2006).  
 
Vascular endothelial growth factor receptor 2 (VEGFR2) 
Most VEGF-A-mediated downstream signaling requires VEGFR2, a 210-
230 kDa glycoprotein, belonging to the type V receptor tyrosine kinase 
subclass. VEGFR2 is considered to be the most potent angiogenic 
mediator, both in physiological and pathological conditions. VEGFR2 
deficient mice die in utero at E8.5, showing severe defects in the 
development of hematopoietic and endothelial cells (Shalaby et al, 
1995), similarly to the homozygous VEGF-A-deficient embryo (Carmeliet 
et al, 1996; Ferrara et al, 1996). VEGFR2 displays stronger kinase activity 
than VEGFR1, even though it binds VEGF-A with a 10-fold lower affinity 
than VEGFR1 (Waltenberger et al, 1994). In this connection, it has been 
proposed that the naturally occurring variation of a single amino acid 
(conserved among type III RTKs) in the activation loop of VEGFR1 is 
responsible for its weaker autophosphorylation (Meyer et al, 2006). 
Remarkably, a pool of autocrine VEGF capable of activating VEGFR2 
intracellularly exist in EC, and this mechanism seems to be required for 
adult vessels homeostasis (Lee et al, 2007). 
VEGFR2 expression 
The VEGFR2 gene is located on chromosome 4; its mRNA is 
predominantly detectable in vascular endothelial cells as well as in their 
embryonic precursors, with a particular abundance in proliferating cells 
(Oelrichs et al, 1993; Quinn et al, 1993; Shalaby et al, 1995). Of note, the 
expression pattern of VEGFR2 and its high affinity ligand VEGF-A are 
correlated both temporarily and spatially (Millauer et al, 1993). Besides 
being highly expressed during embryonic vasculogenesis and 
angiogenesis, a major regulatory role of this protein has been observed 
in neovascularization, both in physiological conditions, such as in the 
utero in response to the estrous cycle (Tasaki et al, 2010), or in 
pathological processes, such as in tumors (Jinnin et al, 2008; Millauer et 
al, 1994; Plate et al, 1993; Shibuya & Claesson-Welsh, 2006).  
The receptor is also present, even if at lower levels, in many other cell 
types, including megakaryocytes, hematopoietic stem cells, osteoblast, 
retinal progenitor cells, adult heart, brain and skeletal muscle (Asahara 
et al, 1999; Lyden et al, 2001; Matsumoto & Claesson-Welsh, 2001; 
Oelrichs et al, 1993; Youssoufian et al, 2007). Interestingly, VEGFR2 was 
found specifically expressed and constitutively phosphorylated in vivo in 
aortic endothelial cells, as well as in several adult mouse tissues, such as 
liver, lung, adipose tissue, and kidney (Maharaj et al, 2006). 
A naturally occurring truncated, soluble form of human and murine 
VEGFR2 arises from alternative splicing, consisting of six Ig-like domains 
with a unique 13 or 16 amino acid C-terminal sequence. It was initially 
found in mouse and human plasma, but so far it has been described in 
many others mouse tissues, including skin, heart, spleen, kidney, ovary 
and in human cornea (Albuquerque et al, 2009; Ebos et al, 2004; Munaut 
et al, 2012). Soluble VEGFR2 (sVEGFR2) does not show any particular 
affinity for VEGF-A; instead, it contains the binding site for VEGF-C, with 
which it interacts, and consequently inhibits lymphangiogenesis, by 
probably trapping VEGF-C and preventing VEGFR3 activation 
(Albuquerque et al, 2009). Consistent with this possibility, sVEGFR2 has 
been shown to play a role in the progression of human malignant tumors, 
being significantly down-regulated during the latest neuroblastoma 
metastatic stages (Becker et al, 2010). In addition, sVEGFR2 mediates the 
interaction between EC and mural cells, leading to mural cell migration 




The crystal structure of the phosphorylated kinase domain of VEGFR2 
resembles closely that of FGFR-1 and the Insulin receptor, revealing a 
high similarity both in conformation and residue positions (McTigue et 
al, 1999). 
The structural domains of which the receptor mainly consists are listed as 
follows: 
• the extracellular domain (residues 20-764) 
• the transmembrane segment (residues 765-785) 
• the juxtamembrane segment (residues 790-833) 
• the proximal kinase domain (residues  834-931).  
• the kinase insert domain (KID) (residues 932-998);  
• the distal kinase domain (residues 999-1158) 
Although not directly involved in catalysis, the KID has been 
demonstrated to be relevant in maintaining competent kinase structure 
and downstream effectors (Heidaran et al, 1991; Severinsson et al, 1990; 
Taylor et al, 1989). The crystallization of the modified VEGFR2 kinase 
domain, containing 18 residues of the KID, yielded for the first time 
partial comprehension of the KID orientation in RTKs, according to which 
the two strands at the end of the KID form a pseudo β–sheet structure 
that may have a key role in structural integrity (McTigue et al, 1999). The 
distal kinase domain contains both the catalytic and the activation loop 
(A loop).  The former is referred to a stretch of residues (H1026-N1033) 
containing an invariant aspartic acid, essential for the phosphotransfer 
reaction; the latter (D1046-E1075) is a flexible region, mainly involved in 
directing protein kinase activity through the phosphorylation of two 
important tyrosine residues located herein.  
As all protein kinases, the catalytic core of VEGFR2 has a typical bi-lobed 
architecture, presenting the proton acceptor, an active site in the cleft 
between the two lobes. The N-terminal lobe (residues 820-920) is the 
smaller one, folded into an antiparallel β-sheet and containing the 
glycine-rich ATP-phosphate binding loop; on the contrary, the C-terminal 
lobe (residues 921-1168) is predominantly formed by α-helices and 
includes the KID as well as the activation and catalytic loops (McTigue et 
al, 1999). The transition from inactive to active states of the receptor is 
governed by conformational changes at the level of these lobes. In 
particular, in the inactive state, a “closed” conformation of the activation 
loop prevents substrate binding, while upon activation tyrosine 
phosphorylation stabilizes it in an “opened” conformation (Roskoski, 
2008) (see http://www.ebi.ac.uk/pdbsum/2oh4 for VEGFR2 crystal 
structure). 
Ligand-induced dimer formation is necessary but not sufficient for 
receptor activation, since distinct orientation of the monomers is 
indispensable as well for driving receptor phosphorylation at specific 
tyrosine residues, with consequent induction of angiogenic signaling 
(Hyde et al, 2012; Kendrew et al, 2011; Tvorogov et al, 2010). Both the 
transmembrane domain and homotypic contacts in membrane proximal 
Ig domains D4 and D7 are mandatory for the formation of active receptor 
dimers (Dosch & Ballmer-Hofer, 2010; Kisko et al, 2011; Ruch et al, 2007; 
Yang et al, 2010); in particular, the enthalpic penalty existing in the 
establishment of D4 and D7 interactions accounts for a possible role in 
preventing ligand-independent activation of VEGFR2 (Brozzo et al, 2012; 
Hyde et al, 2012).  
 
 
Figure 1.9. ECD involvement in VEGFR2 activation. Proper ligand mediate 
receptor dimerization, mainly guided by transmembrane domain and homotypic 
contacts in extracellular domains D4 and D7, are required for giving rise to 
complete transphosphorylation at selected tyrosine residues. Adapted from Hyde, 
Molecular and Cellular Biology 2012 
 
Thus, the ligand-induced dimerization of VEGFR2 ECD, once stabilized by 
the interactions occurring among Ig-like loops, might be communicated 
across the membrane to induce the proper three-dimensional 
organization of the intracellular kinase domain, essential for complete 
receptor transphosphorylation and activation. 
VEGFR2 PTMs 
As the role of VEGFR2 is essential in vascular development, its activity has 
to be finely tuned, and this occurs through gene expression control as 
well as through protein function regulation by post-translational 
modifications (PTMs).  
 
Glycosylation. Soon after protein synthesis, the 150 kDa nascent VEGFR2 
undergoes a first step of rapid N-glycosylation to an intermediate form of 
200 kDa; then, the proper maturation and membrane presentation is 
achieved through a further glycosylation process at slower rate to reach 
the final size of 230 kDa, which corresponds to the only pool capable of 
being phosphorylated in response to ligand stimulation (Takahashi & 
Shibuya, 1997). Consistently, glucose deprivation induces an almost 
complete reduction in VEGFR2 protein levels, by most likely interfering 
with the process of receptor maturation (Adham & Coomber, 2009). 
 
Phosphorylation. The activity of VEGFR2 is strictly dependent on 
receptor dimerization upon ligand binding and consequent 
autophosphorylation of tyrosine residues. The phosphotransfer reaction 
requires the formation of a ternary complex between VEGFR2, ATP and 
the peptide substrate; activation of the receptor seems to be dependent 
on the increased affinity for both substrates (Kendall et al, 1999). The 
phosphorylation of tyrosine residues creates binding sites, which 
modulate the interaction with downstream effectors, especially SH2-
domain-containing proteins, thus leading to the initiation of several 
intracellular cascades in EC. To date, at least six VEGFR2 tyrosine residues 
have been found to be modified in response to VEGF stimulation: Y951 
and Y996, located in the kinase insert region, Y1054 and Y1059 within 
the distal kinase domain, and Y1175 and Y1214 which resides in the C-
terminal tail (phosphorylated tyrosines, from now onward, are indicated 
as pY951, pY996, pY1054, pY1059, pY1175, pY1214) (Dougher-Vermazen 
et al, 1994; Matsumoto et al, 2005; Takahashi et al, 2001). In addition, the 
C-terminal tail shows phosphorylation at positions 1305, 1309, 1319, the 
exact functions of which have not been yet elucidated (Matsumoto et al, 
2005), while the juxtamembrane domain is phosphorylated in Y801, at 
least when the intracellular domain of the receptor is selectively 
purified, and this event appears to precede the modification of the major 
autophosphorylation sites (Solowiej et al, 2009). 
Tyrosines Y1054 and Y1059 are located in the activation loop of the 
receptor, and their VEGF-induced phosphorylation is critical for receptor 
maximal kinase activity (Dougher & Terman, 1999; Kendall et al, 1999). 
Interestingly, once phosphorylated, Y1059 is capable to recruit c-Rous 
Sarcoma (c-Src) kinase, which in turn promotes EC proliferation by 
facilitating the phosphorylation of Y1175 as well as downstream 
effectors, such as IQGAP1 (IQ-GTPase-activating protein) (Meyer et al, 
2008). The phosphorylation of Y951, which occurs preferentially during 
active angiogenesis, creates a binding site for the T cell–specific adapter 
molecule (TSAd) (Matsumoto et al, 2005), alternatively referred as VRAP 
(VEGF receptor associated protein) (Wu et al, 2000). Tyrosine Y1175 
(corresponding to Y1173 in mouse) is considered the essential residue 
for VEGFR2 function; as a matter of fact, knock-in homozygous mice 
carrying a Y1173F mutation die between E8.5 and E9.5 because of severe 
defects in blood vessels formation as well as lack of mature endothelial 
and hematopoietic cells (Sakurai et al, 2005), a phenotype that mirrors 
that of VEGFR2 null mice (Shalaby et al, 1995). The signaling via Y1175 
requires binding of several mediators crucial for vascular development, 
described in detail in the next section. The substitution of Y1214 
(corresponding to 1212 in the mouse) with phenylalanine in knock-in 
mice results in viable and fertile animals, without any obvious 
phenotype, thus indicating that this residue is not essential during 
mouse embryogenesis (Sakurai et al, 2005).  
The rate of phosphorylation of VEGFR2 is tightly controlled through the 
intervention of tyrosine phosphatases, responsible for the maintenance 
of the delicate equilibrium between kinase activation/deactivation, 
necessary to avoid VEGFR2 aberrant over-activation. Among the enzymes 
that limit VEGFR2 signaling, it is important to mention the vascular 
endothelial protein tyrosine phosphatase (VE-PTP) (Mellberg et al, 2009), 
the density-enhanced phosphatase 1 (DEP-1) (Chabot et al, 2009), the 
protein tyrosine phosphatase 1B (PTP1B) (Nakamura et al, 2008) the Src 
homology-2 domain-containing protein tyrosine phosphatase (SHP2) 
(Mitola et al, 2006) and the T-cell protein tyrosine phosphatase (TCPTP) 
(Mattila et al, 2008). 
 
Ubiquitination. Besides dephosphorylation, another important 
mechanism used to counterbalance continuous receptor activation is 
ubiquitination, which routes the receptor for degradation. VEGFR2 is 
ubiquitinated in response to VEGF stimulation (Murdaca et al, 2004) and 
this event is mainly achieved through the involvement of the multi-
adaptor protein Cbl (Duval et al, 2003). The E3 ligase β-transducin 
repeats-containing protein (TRCP) has also been shown to mediate the 
poly-ubiquitination and subsequent degradation of VEGFR2. It is 
recruited to two phosphorylated serines, S1188 and S1191 (Singh et al, 
2005), located in the PEST consensus sequence (rich in proline [P], 
glutamic acid [E], serine [S], and threonine [T]), present in the C-terminal 
tail of VEGFR2 (Meyer et al, 2011). Importantly, the epsin family of 
ubiquitin-binding endocytic clathrin-adaptor protein have recently 
been found to mediate VEGFR2 degradation by binding to the 
ubiquitinated receptor, and their absence leads to aberrant tumor 
angiogenesis due to excessive VEGFR2 signaling, which finally results in 
retarded tumor growth (Pasula et al, 2012).  
 
Oxidation. Compelling evidences has established that the concentration 
of antioxidant present in the environment controls VEGF-induced cell 
signaling (Ushio-Fukai et al, 2002). More precisely, the VEGF-dependent 
oxidation of the reactive cystein thiol (cys-SH) renders VEGFR2 capable of 
sensing the redox state of the endothelium. The thiol oxidation in both 
VEGFR2 and c-Src promotes their interaction and thus c-Src activation 
(Lee et al, 2011). On the contrary, VEGFR2 oxidation in a critical C-
terminal cystein residue is responsible for receptor inactivation and 
defective angiogenesis; peroxiredoxin II is the antioxidant enzyme that 
protects VEGFR2 against oxidative inactivation (Kang et al, 2011). The 
apparent discrepancy arising from these reports highlights the urgent 
need to better elucidate the mechanism connecting VEGFR2 activation 
to the local redox architecture of the endothelium, in both physiological 
and pathological conditions. 
 
VEGFR2 signaling 
As anticipated in the previous section, the capability of VEGFR2 to 
transmit signals inside the cells strongly relies on the phosphorylation of 
critical tyrosine residues, leading to downstream effector recruitment 
and activation of a multiplicity of cellular functions, such as EC 
proliferation, migration, survival and vascular permeability. 
 
Proliferation.  The main way through which VEGF exerts its mitogenic 
effect on EC requires the involvement of phospholipase C-γ (PLCγ), 
recruited by pY1175 on VEGFR2; the subsequent intracellular calcium 
increase and generation of diacylglycerol stimulates protein kinase C 
(PKC) function, which finally leads to the activation of mitogen-activated 
protein kinases (MAPK), among which extracellular-signal regulated 
kinase (ERK) 1 and 2 (Cunningham et al, 1997; Takahashi et al, 2001). 
Notably, the phenotype of PLCγ deficient mice resembles that of Y1173F 
VEGFR2 knock in mice, with embryonic death at E9.0 due to lack of both 
erythrogenesis and vasculogenesis, highlighting the key role of PLCγ in 
transmitting VEGF stimulation (Ji et al, 1997; Liao et al, 2002). Three PKC 
isoforms have been shown to modulate VEGF-induced proliferation: 
PKCα, PKCβ and PKCζ (Wellner et al, 1999; Xia et al, 1996). Although the 
PKC-dependent activation of MAPK pathway was initially shown to occur 
without the participation of Ras-specific guanine nucleotide exchange 
factors (GEFs) (Takahashi et al, 1999), other reports actually demonstrate 
its involvement, predominantly mediated by sphingosine kinase (SPK) 
activity (Meadows et al, 2001; Shu et al, 2002). These conflicting results 
may indicate that different cell types and environment could guide the 
activation of different regulatory components. The PLCgamma/PKC 
pathway controls endothelial cells proliferation also through the 
phosphorylation and consequent activation of protein kinase D (PKD) 
(Wong & Jin, 2005). Finally, the induction of proliferation could 
alternatively be achieved through recruitment to pY1175 of growth 
factor receptor bound protein 2 (Grb2) and Shc [Src homology and 
collagen homology]-related adaptor protein (Sck) (Kroll & Waltenberger, 
1997; Warner et al, 2000). 
 
   
Figure 1.10. VEGFR2 signal transduction. Once the receptor is activated, 
upon VEGFs-induced dimerization, signaling molecules (‘rocket’ shapes) bind to 
respective tyrosine phosphorylation sites and initiate complex network of 
intracellular signal transduction pathways. Adapted from Koch, The Biochemical 
Journal 2012 
 
Migration. Besides proliferation, EC migration is a critical step in blood 
vessels formation. Cell motility is directionally regulated by a 
concentration gradient of chemotactic stimuli and requires degradation 
of the extracellular matrix to allow cell movement. Several signal 
transducers implicated in EC migration have been found to bind 
different phosphorylated tyrosines in VEGFR2, including pY951-
mediated recruitment of TSAd which drives VEGF-A dependent actin 
reorganization and cell migration (Matsumoto et al, 2005). In response 
to VEGF stimulation, Src phophorylates the adaptor protein SH2-domain-
containing adaptor protein b (Shb), which is able to interact with pY1175 
and to subsequently stimulate the phosphorylation of the nonreceptor 
tyrosine kinase focal adhesion kinase (FAK), ending with enhanced 
endothelial cell spreading and migration (Abu-Ghazaleh et al, 2001; 
Holmqvist et al, 2003; Holmqvist et al, 2004). pY1214 mediates complex 
formation between two members of the Src family, namely NCK and Fyn, 
and p21-activated protein kinase-2 (PAK-2) which, in turn, triggers 
subsequent activation of Cdc42 and stress activated protein kinase-2 
(p38) (Lamalice et al, 2006; Lamalice et al, 2004); afterwards, p38 induces 
rearrangements of the actin cytoskeleton by phosphorylating the F-actin 
polymerization modulator, heat shock protein 27 (HSP27) (McMullen et 
al, 2005; Rousseau et al, 1997). Independently of p38, Hsp27 may be 
phosphorylated by PKD, thus inducing VEGF mediated cell migration and 
tubulogenesis (Evans et al, 2008). The phosphorylated PKD also controls 
the transcription of genes involved in endothelial cells migration by 
promoting nuclear export of HDAC5 and HDAC7 (Ha et al, 2008; Wang et 
al, 2008). VEGFR2 phosphorylation induces its interaction with the 
docking proteins Grb-2 associated binder 1 and 2 (Gab1 and Gab2), most 
likely through Y801 and Y1214 since mutation of both abrogates Gab1 
phosphorylation (Caron et al, 2009). Gab1-depleted cells show reduced 
ability to migrate (Dance et al, 2006; Laramee et al, 2007), and, more 
importantly, Gab1 knock out mice display impaired VEGF-induced 
angiogenesis (Lu et al, 2011). IQGAP1 has also been linked to VEGFR2-
induced cell migration (Yamaoka-Tojo et al, 2006), as well as PLCβ3 
(Bhattacharya et al, 2009) and Rho-dependent kinase (ROCK) (Le Boeuf et 
al, 2006). 
 
Survival. Another event considerably relevant for vessel development 
and maintenance is the control of EC apoptosis. The survival function of 
VEGF has already been explained by the induction it exerts on the 
expression of antiapoptotic proteins, such as Bcl2 (B cell CLL/lymphoma 
2), the X-chromosome linked inhibitor of apoptosis protein (XIAP) and 
survivin (Nor et al, 1999; Tran et al, 1999). VEGFR2 activity tightly governs 
this process by mainly signaling through the PI3K-Akt pathway, which 
mediates the survival cue (Gerber et al, 1998). Akt (also known as PKB) is 
capable of inhibiting the apoptotic activity of downstream targets, such 
as Bcl2-associated death promoter (BAD) and caspase 9 (Jiang & Liu, 
2009). Akt1 is the predominant form in EC, and it was shown to be crucial 
for VEGF-mediated angiogenesis (Ackah et al, 2005; Chen et al, 2005b). 
Interestingly, the VEGFR2-dependent activation of Akt is strictly related 
to EC anchorage (Fujio & Walsh, 1999) and, in particular, to the proper 
function of the adhesion molecule Vascular Endothelial Cadherin (VE-
cadherin) (Carmeliet et al, 1999a). On the other side, the impairment in 
p38 MAPK phosphorylation and activity has also been associated with 
reduced EC apoptosis (Kumar et al, 2004; Yilmaz et al, 2003). 
 
Permeability. The original designation of VEGF-A was “vascular 
permeability factor” (VPF), because of its critical action on microvascular 
permeability (Senger et al, 1983). Vascular permeability to solute and 
proteins as well as white blood cells is pivotal in both physiological and 
pathological conditions (Bates & Harper, 2002; Dvorak et al, 1999; Mehta 
& Malik, 2006), and it has been proposed to occur either through 
transendothelial pores formation or through transient opening of EC 
junctions (Vandenbroucke et al, 2008). 
Mice lacking c-Src or Yes display reduced VEGF-mediated vascular 
permeability, despite their apparently normal vascular development 
(Eliceiri et al, 1999); in particular, c-Src was shown to elicit the disruption 
of intercellular junctions by phosphorylating VE-cadherin (Wallez et al, 
2007; Weis et al, 2004), and thus promoting its rapid endocytosis and 
internalization into clathrin-coated vesicles (Gavard & Gutkind, 2006). 
Nevertheless, other signaling pathways may concur to cause loss of 
endothelial barrier function besides src-induced VE-cadherin 
phosphorylation (Adam et al, 2010). Importantly, the transmembrane 
binding partner VE-PTP decelerates the junctions opening by exerting 
its tyrosine phosphatase activity on VE-cadherin (Nawroth et al, 2002; 
Nottebaum et al, 2008). The maintenance of such a delicate equilibrium 
may also involve angiopoietin receptor Tie-2, with which VE-PTP 
interacts (Winderlich et al, 2009). Moreover, EC junction rearrangement 
in response to VEGF requires the TSAd-dependent Src activation, both of 
which are found in complex with VE-cadherin and VEGFR2 (Sun et al, 
2012). Alternatively, VEGF may prompt vascular permeability through 
the endothelial nitric oxide synthase (eNOS) (Fukumura et al, 2001), the 
activation of which is, in turn, dependent on PI3K/Akt pathway 
(Dimmeler et al, 1999; Fulton et al, 1999). However, as demonstrated in 
mice lacking the Akt1 isoform, its connection with permeability is 
bridged by the vascular regulator thrombospondins 1 (TSP-1) and 2 (TSP-
2) (Chen et al, 2005b). 
 
VEGFR2 internalization 
Dynamic and quick VEGFR2 response to growth factors present in the 
tissue environment requires high rates of receptor turnover, either in 
terms of rapid clearing of activated receptor from plasma membrane as 
well as eventual sustained intracellular signaling. 
Since in the absence of maximal receptor autophosphorylation the 
levels of internalization are significantly lowered (Dougher & Terman, 
1999), a model has been proposed by which ligand binding and 
consequent receptor activation triggers clathrin-dependent 
endocytosis, which depends on the receptor interaction with both VE 
cadherin and ephrin-B2 receptor (Lampugnani et al, 2006; Salikhova et al, 
2008; Sawamiphak et al, 2010). In particular, two ephrin-B2 partners, 
namely clathrin-associated sorting protein Disabled 2 (Dab2) and cell 
polarity regulator PAR-3, are pivotal in the regulation of VEGFR2 
internalization (Nakayama et al, 2013). Nevertheless, extremely low rate 
of endocytosis persistence, even in the absence of VEGF-A stimulation, 
accounts for a plausible constitutive recycling in quiescent endothelial 
cells (Ewan et al, 2006; Jopling et al, 2011). As a matter of fact, in 
unstimulated cells, a substantial fraction of VEGFR2 is found localized in 
early endosomes and in two distinct vesicular compartments 
characterized by the presence of Rab5 or Rab4 GTPase, the former 
compartment responsible for driving the transfer of protein from plasma 
membrane to early endosomes, the latter for targeting proteins back to 
the plasma membrane (Ballmer-Hofer et al, 2011; Jopling et al, 2009).  
                                         
 
Figure 1.11. VEGFR2 trafficking. After receptor activation upon ligand 
binding, several factors, among which Ephrin B2, Neuropilin 1, Synectin, are 
engaged to induce VEGFR2 mobilization from plasma membrane to endocytic 
vesicles. Afterwards, the receptor might either be recycled back to the plasma 
membrane or targeted for degradation. See text for details. Adapted from 
Horowitz, Cellular Signalling, 2012 
 
 
Upon VEGF stimulation, things appear more complex. First, VEGF-A elicits 
the mobilization of VEGFR2 from the trans-Golgi apparatus to 
cytoplasmic vesicles; Syntaxin 6, a Golgi-localized soluble N- 
ethylmaleimide attachment protein receptor (t-SNARE), is responsible 
for the depletion of VEGFR2 from this Golgi pool, and its inhibition 
results in increased receptor lysosomal degration (Manickam et al, 2011). 
For VEGFR2 recycling back to the plasma membrane an additional 
passage from Rab4 to Rab11 associated vesicles is required (Ballmer-
Hofer et al, 2011). Another unique feature is the dependence of VEGFR2 
trafficking on its co-receptor, NP1, which most likely acts in concert with 
Sinectin (also referred as GAIP-interacting protein, C-terminus, GIPC) to 
allow the receptor to reach the external membrane. The dissociation 
between VEGFR2 and NP1 causes progression to Rab7-associated late 
endosomes and lysosomes, thus routing the receptor for degradation 
(Ballmer-Hofer et al, 2011; Jopling et al, 2009; Lanahan et al, 2010). 
Ubiquitination as well routes the receptor for degradation; proteasome 
inhibition prolongs the duration of VEGFR2 signaling, thus confirming 
the involvement of the proteasome proteolytic pathway in the negative 
regulation of VEGFR2 activity (Bruns et al, 2010; Ewan et al, 2006; Pasula 
et al, 2012).  
Interestingly, even after internalization, the receptor retains the ability 
to transduce the signals, either from early or from recycling Rab4/Rab5-
associated endosomes (Ballmer-Hofer et al, 2011; Bruns et al, 2010; 
Jopling et al, 2009; Lampugnani et al, 2006; Lanahan et al, 2010; 
Nakayama et al, 2013; Sawamiphak et al, 2010); in particular, the ERK and 
Akt pathways are upregulated upon VEGFR2 endocytosis, while, on the 
contrary, p38 activation is responsive to matrix-bound rather than 
soluble VEGF-A (Chen et al, 2010). On the other hand, PTP1b may 
counterbalance this sustained signaling by dephosphorylating the 
receptor near the plasma membrane (Anderie et al, 2007; Lanahan et al, 
2010). 
Caveolin-1, dynamin-2 and ADP-ribosylation factor 6 (ARF6) are other 
important interacting partners able to regulate the rate of VEGFR2 
endocytosis and thus influence VEGF-induced angiogenesis (Bauer et al, 
2005; Bhattacharya et al, 2005; Ikeda et al, 2005; Labrecque et al, 2003). 
The adaptor/scaffoding protein Cerebral cavernous malformation 3 
(Ccm3), the mutation of which causes vascular malformation in the brain, 
is also linked to VEGFR2 internalization, by probably stabilizing it at the 
cell surface (He et al, 2010). 
 
Other VEGFRs and coreceptors 
VEGFR1 
VEGFR1 is a 180 kDa glycoprotein expressed in vascular endothelial cells 
and in a range of non-endothelial-cells, among which macrophages and 
monocytes, vascular smooth muscle cells, dendritic cells, hematopoietic 
stem cells and cardiomyocytes (Barleon et al, 1996; Clauss et al, 1996; 
Dikov et al, 2005; Dikov et al, 2001; Grosskreutz et al, 1999; Kaipainen et 
al, 1993; Sawano et al, 2001). It is activated by three different 
components of the VEGF family, namely VEGF-A (de Vries et al, 1992), 
VEGF-B (Olofsson et al, 1998) and PlGF (Park et al, 1994).  
Gene targeting studies demonstrate its essential role during 
embryogenesis, since Flt-1-/- mice die in utero between day 8.5 to 9.0 
because of an overgrowth of endothelial-like abnormal cells and a failure 
in vascular channel organization (Fong et al, 1995; Fong et al, 1999). 
Unexpectedly, the importance of the receptor could not be attributed 
to its signal transduction activity; on the contrary, this seems 
dispensable, since mice expressing the receptor lacking the tyrosine 
kinase domain (VEGFR1 TK(-) mice), but still able to bind VEGF, develop 
without any overt effect and with an essentially normal vasculature 
(Hiratsuka et al, 1998). As a matter of fact, VEGFR1 displays a strong 
affinity for VEGF-A, but, in contrast, an extremely weak kinase activity and 
tyrosine phosphorylation (de Vries et al, 1992; Waltenberger et al, 1994), 
explained in part by a natural occurring inactivating amino acidic 
replacement in the activation loop (Meyer et al, 2006) and in part by the 
presence of a repressor sequence in the juxtamembrane domain (Gille 
et al, 2000). Given these compelling evidences, VEGFR1 has been 
proposed as a “decoy” receptor, able to regulate vascular formation most 
likely by trapping VEGF-A and thereby preventing activation of VEGFR2 
(Shibuya, 2001). Not only the full-length membrane-bound form of 
VEGFR1 but also a soluble, secreted form of the receptor, called 
sVEGFR1/sFlt, may be able to inhibit VEGF activity either by sequestering 
the growth factor or heterodimerizing with VEGFR2 (Kendall & Thomas, 
1993; Kendall et al, 1996). Arising from alternative splicing, sVEGFR1 
lacks the intracellular part of the protein and the seventh Ig-like 
extracellular domain but possesses a unique 31-aa hydrophilic C-
terminal tail (Kendall & Thomas, 1993; Shibuya et al, 1990). 
Physiologically, this endogenous VEGF-A trap in adult life is essential for 
corneal avascularity (Ambati et al, 2006; Ambati et al, 2007), while, 
pathologically, its abnormal upregulation has been found in the 
hypertrophic myocardium at the onset of failure (Kaza et al, 2011) as well 
as in serum and placenta of patient with preeclampsia (Maynard et al, 
2003). Surprisingly, about half of the mice expressing only sVEGFR1 die in 
utero because of poor vessels development, thereby underlying the 
importance of the membrane-anchored form in VEGF-A signaling 
regulation (Hiratsuka et al, 2005). 
Irrespective of this negative regulatory role assigned, the 
phosphorylation of several VEGFR1 tyrosine residues was found to drive 
the induction of different interacting partners (among which p38/PI3K, 
PLCγ, SHP2, GRB2 and Nkc) (Koch et al, 2011; Olsson et al, 2006). 
Additionally, different VEGFR1 ligands, such as VEGF-A and PlGF, may 
induce different phosphorylation patterns (Autiero et al, 2003).  
Thus, VEGFR1 has been shown to transmit VEGF signals and stimulate the 
migration of both endothelial cells (Cai et al, 2003; Kanno et al, 2000; 
Wang et al, 2011) and non endothelial cells, such as 
monocytes/macrophages (Barleon et al, 1996; Clauss et al, 1996; Lyden et 
al, 2001; Zacchigna et al, 2008b) and tumor cell lines (Lesslie et al, 2006; 
Taylor et al, 2010). In addition, during pathological conditions the PlGF-
induced activation of VEGFR1 might favor angiogenesis, either by 
inducing distinct intracellular signals or by displacing VEGF-A and making 
it available for VEGFR2 (Autiero et al, 2003). In cardiomyocytes, VEGFR1 is 
specifically upregulated in cells exposed to hypoxic conditions and 
oxidative stress. More importantly, activation of the receptor upon VEGF-
B167 stimulation eventually improves cardiac function after myocardial 
infarction (Zentilin et al, 2010). Moreover, the increased expression and 
activation of VEGFR1 upon copper addition to primary cultures of 
neonatal cardiomyocytes was found to mediate the copper-induced 
regression of cardiomyocyte hypertrophy (Zhou et al, 2009). Finally, 
VEGFR1 was also involved in the initiation of the pre-metastatic niche by 
inducing the migration of haematopoietic bone marrow progenitors 
(Kaplan et al, 2005), although this finding was later debated (Dawson et 
al, 2009a; Dawson et al, 2009b). 
 
VEGFR3 
VEGFR3 is the cognate receptor of VEGF-C and VEGF-D, that generates 
from the proteolytic cleavage of a 195 kDa precursor, resulting in an N-
terminal peptide bound to the rest of the protein through disulphide 
bonds. Two conserved tyrosine residues in the kinase domain of VEGFR3 
are responsible for its kinase activity, and five additional tyrosine 
phosphorylation sites through which it interacts with downstream 
effectors have been identified in the C-terminal tail (Dixelius et al, 2003; 
Salameh et al, 2005). VEGFR3 exists in two isoforms generated by 
alternative splicing, the shorter of which results in a protein lacking the 
C-terminal 65 amino acids (Hughes, 2001; Pajusola et al, 1993), and 
consequently the two autophosphorylation sites therein located 
(Dixelius et al, 2003). Signal transduction downstream to VEGFR3 
involves SH2 domain protein C2 (Shc2) and Grb2, ERK 1/2, PI3K-Akt, and 
the adaptor protein C10 regulator of kinase (CRK) I/II, and contribute to 
proliferation, migration, survival of lymphendothelial cells (Koch et al, 
2011). 
In the adult its activity has been mainly linked to the maintenance of 
lymphatic endothelium (Alitalo et al, 2005), where it is predominantly 
expressed since the later stage of development (Kaipainen et al, 1995). 
Notably, mutations in VEGFR3 have been identified in patients with 
primary lymphoedema (Ghalamkarpour et al, 2006; Irrthum et al, 2000; 
Karkkainen et al, 2000). Nevertheless, during embryogenesis VEGFR3 has 
an important function in blood vessel development, since VEGFR3 gene 
targeted mice exhibit defects in the organization of the vasculature and 
die at E9.5 because of cardiovascular failure (Dumont et al, 1998). As it 
happens for VEGFR1, mice expressing a kinase deficient VEGFR3, with the 
ligand-binding region still functional, present normal blood vessel 
development (Zhang et al, 2010). Thus, VEGFR3 might regulate 
angiogenesis either by trapping VEGF-C or by modulating VEGFR2 
activity forming heterodimers. Consistent with this notion, antibodies 
neutralizing VEGFR3, by blocking both VEGFR3 homodimer and 
VEGFR3/VEGFR2 heterodimer formation, suppress vascular and lymphatic 
EC migration and vessel sprouting (Tvorogov et al, 2010). Recent data 
have extended the role of VEGFR3 in angiogenesis also during the adult 
life, according to which the blockage of VEGFR3 signaling results in 
decreased sprouting, vascular density, vessel branching and EC 
proliferation in the mouse (Tammela et al, 2008).  
VEGFR3 is also found to be upregulated in the tumor vasculature, thus 
opening the possibility to exploit VEGFR3 targeting agents to inhibit 
tumor growth (Kubo et al, 2000; Laakkonen et al, 2007; Smith et al, 2010).  
Finally, VEGFR3 has also been found in neuronal progenitor cells (Le Bras 
et al, 2006), osteoblasts (Orlandini et al, 2006) and macrophages 
(Schmeisser et al, 2006). 
 
Neuropilins 
VEGFs display different ability in interacting with co-receptors, such as 
Neuropilins and heparan sulphate proteoglicans (HSPGs) (Ruhrberg et al, 
2002), which are broadly defined as cell-surface expressed molecules 
that are devoid of any known intrinsic catalytic activity.  
Neuropilins (NP1 and NP2) are transmembrane glycoproteins of about 
130 kDa, initially identified as receptors for class 3 semaphorins, soluble 
axon guidance molecules implicated in the regulation of neural and 
vascular development (Chen et al, 1997; Fujisawa, 2004; He & Tessier-
Lavigne, 1997; Kolodkin et al, 1997; Larrivee et al, 2009). They were later 
shown to also interact with VEGF family members, such as VEGF-A165, to 
which they both bind with different affinity (Geretti et al, 2007; Soker et 
al, 1998) and VEGF121 (Pan et al, 2007; Shraga-Heled et al, 2007). In 
addition, NP1 binds VEGF-B and PlGF, whereas VEGF-C and VEGF-A145 are 
ligands for NP2 (Neufeld et al, 2002; Xu et al, 2010). Even if NP1 and NP2 
share only 44% homology, they have similar structural features with a 
short intracellular domain of 40 amino acids lacking enzymatic activity 
(Fujisawa et al, 1997). Nonetheless, despite structural homologies, NP1 
and NP2 differ for signal properties, as NP1 deficient mice die during 
mid-gestation with defects in the heart, vasculature, and nerve 
projection (Kawasaki et al, 1999), while NP2 KO mice are viable and 
display only defects in nerve projection (Chen et al, 2000; Giger et al, 
2000). Notably, the double NP1/NP2 knockout mouse has a more severe 
abnormal vascular phenotype than either NP1 or NP2 single knockouts, 
resembling the phenotypes of VEGF and VEGFR2 knockouts (Takashima et 
al, 2002). Importantly, Neuropilins are able to directly interact with 
VEGFRs and thus potentiate the ligand–induced activation by enhancing 
the association between growth factors and the main receptor. NP2 has 
been shown to be predominantly present in veins and lymphatics during 
development (Herzog et al, 2001; Yuan et al, 2002) and, in agreement, it 
interacts with VEGFR3 in response to VEGF-C stimulation (Xu et al, 2010). 
On the contrary, NP1 is mainly expressed in arteries (Gu et al, 2003; 
Herzog et al, 2001), and forms complexes with VEGFR2 and VEGF-A 
(Prahst et al, 2008; Soker et al, 2002; Whitaker et al, 2001), thus 
enhancing VEGFR2-mediated signaling (Shintani et al, 2006), as it was 
demonstrated for sprouting angiogenesis (Kawamura et al, 2008), EC 
migration (Herzog et al, 2011) and permeability (Becker et al, 2005). 
Moreover, it cannot be excluded that these molecules could transduce 
the signal independently of VEGFRs; as a matter of fact, compelling 
evidences suggest that NP1 may stimulate cell migration and adhesion 
also in the absence of VEGFR2 involvement (Murga et al, 2005; Wang et 
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Cell culture and treatment 
PAE and PAE/KDR cells, kindly provided by L. Claesson-Welsh (Uppsala 
University, Sweden), were grown in HAM’s F12 medium (Gibco, Life 
Technologies) supplemented with 10% FBS. Pooled human umbilical 
vein endothelial (HUVE) cells were cultured in EBM supplemented 
medium (both from Clonetics, Lonza) until the third passage. Cells were 
plated and grown in gelatin 0.1% coated dishes for at least 24 hours. 
HEK293T cells were maintained in Dulbecco’s modified Eagle Medium 
with 10% FBS.  
Recombinant human VEGF-A165 (rhVEGF) was purchased from R&D and 
was used after serum starvation at a final concentration of either 50 
ng/ml in PAE and PAE/KDR cells or 20 ng/ml in HUVE cells for the 
indicated times. Cells were treated with trychostatin A (TSA; SIGMA) for 6 
hrs, 500 nM for PAE/KDR cells, 1 μM for HEK293T cells and 10 μM for HUVE 
cells. 
MS275 and MC1575 were provided by A. Mai and used at a final 
concentration of 10 μM. Nicotinamide (NAM) was purchased from 
(SIGMA) and used at a final concentration of 20mM. 
The cellular treatment with Lys-CoA (synthesized at the ICGEB Peptide 
Synthesis Core Facility) was performed as described (Bandyopadhyay et 
al, 2002) with minor modifications. Briefly, 16x106 exponentially 
growing HEK293T cells, transfected or not with pCDNA3-VEGFR2-Flag, 
were incubated with the ICB solution (10 mM HEPES, pH 7.0, 0.14 M KCl, 
0.01 M NaCl, and 2.4 mM MgCl2) containing Lys-CoA (0.75 mM) and SPC 
(1.2 mg/ml) at 37°C for 20 min. Upon LysCoA treatment, cells were plated 
for additional 24 hours and then lysed as described. 
 
Transfection and plasmids 
Transfections were performed either by the standard calcium phosphate 
co-precipitation procedure in HEK293T cells or using Lipofectamine 
(Invitrogen, CA) in PAE and PAE/KDR cells, according to the 
manufacturer’s protocol. 
pCDNA3-mouse VEGFR2 was kindly provided by F. Bussolino (University of 
Torino and IRCC, Torino, Italy). Starting from this plasmid, the construct 
pCDNA3-VEGFR2-Flag was obtained by inserting a Flag tag fused to the C-
terminal part of VEGFR2. Site directed mutagenesis was carried out to 
construct the VEGFR2 mutants using pCDNA3-mouse VEGFR2 as a PCR 
template, with primers specific for the mutated version: K1053R and 
K929R-K937R-K939R-K947R. Starting from the flagged constructs of both 
wt and mutants VEGFR2, the catalytic domain (aa 806-1356) was 
amplified by PCR and cloned into pET-15b vector, carrying an N-terminal 
His Tag sequence (His-VEGFR2 constructs). pCDNA3-p300 was previously 
described (Marzio et al, 1998). The pCMV-p300-DY-myc mutant was 
kindly provided by T.P. Yao (Durham). pCDNA3-HA-GCN5 was generated 
by A. Sabo as previously reported (Sabo et al, 2008). Human Flag-tagged 
HDAC5 and HDAC6 were purchased from Addgene. 
 
Antibodies 
Anti-VEGFR2 antibody, either free or conjugated with agarose beads, 
anti-HA, anti HDAC5 and HDAC6, and anti p300 antibodies were 
purchased from Santa Cruz. Anti-Flag, either free or conjugated with 
agarose beads, and anti-tubulin, were both from SIGMA. Anti-total acetyl-
lysine, anti phospho-VEGFR2 1173, anti-phospho-ERK 1/2 and anti-ERK 
antibodies are from Cell Signaling Technology (MA); anti phospho-
VEGFR2 1054, clone D1W, was purchased from Millipore; anti-total 
phospho-tyrosine, clone 4G10 was from Upstate. Horseradish peroxidase-
conjugated secondary antibodies for western blotting detection were 
purchased from DAKO. 
 
Western blot and immunoprecipitation 
Cell lysis was performed using modified RIPA (150 mM NaCl, 50 mM 
TrisHCl pH 7.4, 1 mM EDTA, 1% NP-40, 0.25% Sodium-deoxycolate) or 
biotinylation lysis buffer (Tris HCl 10 mM, pH 7.5, NaCl 50 mM, 0.5% NP-
40, 10% Glycerol, 5mM EDTA), supplemented with protease inhibitors 
tablets (Roche), Sodium Fluoride 1mM, Sodium Butirrate 10mM and 
Sodium Orthovanadate 1mM, TSA 10 μM and NAM 10mM (all from 
SIGMA). Protein lysate concentration was determined by Bradford Assay 
(BIORAD). Immunoprecipitation was carried out either with anti-Flag or 
anti VEGFR2 beads. Cells extracts where incubated for 3 hours, in co-
immunoprecipitation assay, or overnight with conjugated beads, and 
then washed in lysis buffer. Immunoprecipitates were loaded onto 6% 
SDS page and electroblotted to PVDF transfer membrane (GE 
Healthcare); proteins were subsequently detected after incubation with 
specific antibodies. After detection of either phosphorylation or 
acetylation of proteins, membranes were incubated in stripping buffer 
(100mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7) at 60°C for 
30 min and the amounts of the total protein were detected. Western 
blot are representative of at least three independent experiments. Band 
intensity was calculated using the ImageJ software. 
 
In vitro acetylation assay  
HAT assays were performed as previously reported, with minor 
modifications (Cereseto et al, 2005). Briefly, 500 ng His-VEGFR2 fusion 
proteins were incubated with the GST-HAT domain of p300 and 14C-
acetyl-CoA (Perkin Elmer,60mCi/mmol) in HAT buffer (50 mM Tris, pH 7.5, 
1% glycerol, 50mM sodium butyrate) for 1 hour at 30°C. Acetylated 
proteins were then visualized by phospho-imaging (Cyclone) after 
separation by SDS–PAGE. To check protein loading, the 8% acrilamide 
gels were stain with Roti-Blue (Carl Roth GmbH) and dried 2hrs at 80°C. 
The extent of in vitro acetylated recombinant VEGFR2 was calculated as 
Density Light Unit (DLU) according to the Optiquant software analysis. 
 
In vitro kinase assay 
In vitro VEGFR2 kinase activity was assayed using an enzyme-linked 
immunosorbent assay kit. 500 ng of His-VEGFR2 recombinant protein 
were incubated with 20 μM ATP, 1.25 mM DTT and 6 μM Poly (Glu-Tyr) 
Biotinylated Peptide (Cell Signaling) in Tyrosine Kinase Buffer (60 mM 
HEPES pH 7.5, 5 mM Mg Cl2, 5 mM Mn Cl2, 3 μM Na3VO4) at room 
temperature for 30 minutes; the reaction was stopped with 50 mM EDTA 
pH 8 and the samples were subsequently transferred to a 96-well 
streptavidin-coated plate (Thermo Scientific) and incubated at room 
temperature for 1 hour to allow the binding of the biotinylated peptide 
to streptavidine. Substrate phosphorylation was then monitored using a 
phopshotyrosine-specific monoclonal antibody, followed by recognition 
with an appropriate horseradish peroxidase-conjugated secondary 
antibody and colorimetric ELISA detection assay. 
 
Immunofluorescent staining 
HUVE cells were starved for 6 hours the day after plating, and then 
treated with rhVEGF for fixed times. After fixation with 4% buffered 
paraformaldehyde (PFA) and permeabilization with PBS-T-T buffer 
(Tween 0.2% and Triton 0.1%), cells were incubated with the primary 
antibody O/N at 4°C, followed by appropriate secondary antibodies. 
Nuclei were detected with Toto-3 stain, final concentration 100 nM (Life 
technologies). Coverslips were mounted using Vectashield mounting 
medium (Vector laboratories) and the samples were examined using an 
LSM 510 META confocal microscope (Carl Zeiss Microimaging) with an 
X63 NA 1.4 Plan-Apochromat oil objective. The pinhole of the 




Immunoprecipitated proteins were separated by SDS-PAGE and the 
VEGFR2 bands, after Zinc staining (Pierce), were processed for analysis by 
mass spectrometry. In order to maximize the detection of acetylated 
peptides, the protein bands were treated with deuterated acetic 
anhydride (Sigma Aldrich), as this treatment normalizes the suppression 
of ionization caused by acetylation (Smith, 2005). This treatment results 
in the addition of deuterated acetyl groups on the lysine residues that 
were not acetylated in vivo and results in a mass shift of +42 for the in 
vivo acetylated lysine residues and +45 for the in vitro acetylated 
residues. Following treatment with deuterated acetic anhydride, the 
samples were digested with trypsin, extracted from the gel, the N-
termini were labeled with ICPL light reagents (Bruker Daltonics) and 
analyzed by LC-MALDI mass spectrometry essentially as previously 
described (Bish et al, 2008). The resulting spectra were analyzed using 
the X!tandem search engine using the ENSEMBL mouse protein database 
(release GRCm37). 
 
Cell surface biotinylation assay 
The assay was performed as previously described (Meyer et al, 2004), 
with minor modifications. Briefly, PAE cells were transfected with the 
indicated plasmids and serum starved over night. After 5 min of 
stimulation with rhVEGF, cells were washed three times with ice-cold 
PBS containing Ca2+ and Mg2+(Ca2+/Mg2+ PBS) and then surface proteins 
were selectively labeled by treatment with 0.5 mg/ml of thiol-cleavable 
Sulfo-NHS-S-S-Biotin (Pierce, Thermo Scientific) for 30 min on ice. 
Unreacted biotin was quenched and removed by three washes with ice-
cold H/S buffer (25 mM HEPES, pH 7.4 and 150 mM NaCl). Cells were then 
washed on ice twice with Ca2+/Mg2+ PBS and lysed with ice-cold lysis 
buffer. Equal amounts of proteins from each sample were incubated with 
Streptavidin agarose resins (Pierce, Thermo Scientific) on a rotating 
wheel overnight at 4°C. Beads were then washed five times with lysis 
buffer and boiled at 95°C in SDS sample buffer before proceeding with 
western blot analysis. 
Computational modeling 
Molecular Dynamics simulations were performed using the generalized 
Born model approach for implicit solvation as implemented in the 
AMBER package (Tsui & Case, 2000). A time step of 2 femtoseconds and a 
cut off of 1.8 nm was adopted. All the systems were stabilized by 0.2 
nanoseconds, during which the temperature was linearly raised from 0 
to 300 K coupling the systems to a Langevin thermostat with a collision 
frequency of 2/picosecond (Loncharich et al, 1992). Subsequently, 25 
nanoseconds of production runs were performed for all the simulated 
systems. The solvent accessible surface (SAS), reported in Figure 5G was 
calculated on residues Asp1050 to Ala1063. 
 
Wound healing assay  
PAE cell transiently expressing either wt VEGFR2 or the M5 mutant were 
grown to 100% confluence on 12-well plates. After 24 h of serum 
starvation, the confluent monolayer was mechanically scratched with a 
sterile p200 pipette tip to create a cell-free zone. Cells were then 
washed to remove the debris and kept in the absence of serum or 
stimulated with rhVEGF; to block cell proliferation, thymidine 0.25 μM 
was added to the medium during the 24 hours of stimulation. Phase 
contrast images were taken immediately after the scratch (time 0) and 
24 h after, and the scratched areas were imaged at both time points 
using a DM IL LED microscope (Leica). The area of the wound (area 
between the edges of the scratched cell monolayer) was determined at 
both time points using Volocity 5.5 software (Perkin Elmer). Endothelial 
cell migration was calculated by subtracting the wound area at time 24 h 
with that at time 0. 
 
Statistical analysis  
Pair-wise comparison between groups was performed using the two-
tailed Student’s t test. P values of 0.05 or less were considered as 












VEGFR2 is acetylated in endothelial cells 
Given the essential role that VEGFR2 exerts in vascular development, it is 
not surprising that many mechanisms exist to finely tune its activity. 
Among these, post-translational modifications of the mature protein 
have a preeminent role. Besides phosphorylation (Dougher & Terman, 
1999; Matsumoto et al, 2005; Takahashi et al, 2001), receptor 
glycosylation is required for proper maturation and membrane 
presentation (Takahashi & Shibuya, 1997), while Cbl-mediated 
ubiquitination routes the receptor for degradation (Duval et al, 2003; 
Murdaca et al, 2004).  As extensively discussed in the previous section, 
among the most prominent PTMs, lysine acetylation has emerged in the 
last decade as a crucial modification that regulates several cytoplasmic 
processes by targeting non-histone proteins and giving rise to complex 
regulatory programs in synergy with other PTMs  (Choudhary et al, 2009; 
Spange et al, 2009; Xiong & Guan, 2012; Yang & Seto, 2008a; Zhao et al, 
2010).  
Therefore, we wondered whether VEGFR2 might also be modified by 
acetylation in EC. To address this question, we first immunoprecipitated 
the endogenous receptor from whole cell lysates (WCL) of primary 
human umbilical vein endothelial cells (HUVE cells), and then probed the 
immunoprecipitated proteins with an antibody specific for acetyl-
modified lysines. The endogenous VEGFR2 is ordinarily detected as a 
doublet of bands in the cell lysates, of which the lower one corresponds 
to the immature, partially glycosylated form of the protein, and the 
upper one to the mature, highly glycosylated receptor. Both bands were 
detected as acetylated (Figure 3.1, panel A).  
Blockage of the deacetylase activity by cell treatment with the class I/II 
histone deacetylase inhibitor trichostatin A (TSA) (Yoshida et al, 1995) 
caused hyperacetylation of VEGFR2 (Figure 3.1 panel A, compare lane 1 
and lane 2), without affecting protein level. The same result was 
confirmed in another cellular model, Porcine Aorthic Endothelial cells 
stably expressing human VEGFR2 (PAE/KDR) (Waltenberger et al, 1994) 
(Figure 3.1, panel B).  





 Figure 3.1. VEGFR2 acetylation in endothelial cells. WCL was 
immunoprecipitated using an anti-VEGFR2 antibody, and then 
immunoblotted with an anti-acetyl lysines antibody. Upon stripping, the 
same membrane was immunoblotted with an anti-VEGFR2 antibody. 
HUVE cells (A) or PAE/KDR cells (B) were treated either with TSA or 
DMSO as a control, as indicated on top of each lane. 
p300 acetylates VEGFR2 in endothelial cells 
In order to identify the lysine acetyltransferase (HAT) responsible for 
VEGFR2 acetylation, we tested the members of two main classes of KATs, 
namely p300, for p300/CBP family, and GCN5 and P/CAF, for the GNAT 
family. The in vivo acetylation assay were performed by overexpressing 
these enzymes in PAE KDR cells followed by receptor 
immunoprecipitation from WCL and blotting with anti-acetyl lysine 
antibody. Among all the acetyltransferases tested, p300 was the only 
enzyme effective at catalyzing VEGFR2 acetylation (Figure 3.2, panel A). 
The activity of p300 was neither cell type nor species specific, as these 
findings were reproduced in HEK293T cells cotrasfected with mouse 
VEGFR2 in combination with p300, GCN5-HA and P/CAF-Flag; moreover, 
in this condition, only p300 showed the ability to co-immunoprecipitate 
with VEGFR2 (Figure 3.2, panel B).  
So far, p300 activity has been extensively characterized in the nucleus, 
where it regulates acetylation of both histones and transcriptional 
activators (Bedford et al, 2010; Goodman & Smolik, 2000), whereas 
VEGFR2 is a transmembrane receptor. Despite their apparently different 
compartment distribution, these proteins physically interact at the 
endogenous level inside EC, as demonstrated by the results obtained by 
immunoprecipitating the endogenous receptor and then probing the 
immunoprecipitates with an antibody specific for p300 (Figure 3.3). To 
check the specificity of this interaction, a WCL was incubated, in parallel, 
with beads conjugated with rabbit IgGs (lane corresponding to IgG only). 





Figure 3.2. p300 induces VEGFR2 acetylation. (A) PAE/KDR cells were 
transiently transfected with p300, GCN5 or P/CAF and the acetylation 
levels of VEGFR2 were assessed by receptor immunoprecipitation and 
blotting with an anti-acetyl lysine antibody, followed by stripping and 
probing with an anti-VEGFR2 antibody. The WCL were probed with anti-
p300, anti-HA, anti-Flag and anti-tubulin antibodies. (B) The same 
experiment was performed in HEK293T cells transiently transfected with 
mouse VEGFR2, p300, GCN5 or P/CAF. Additionally, the HEK293T 





Figure 3.3. p300 co-immunoprecipitate with VEGFR2 in EC. HUVE cells 
were treated either with TSA or DMSO, followed by WCL 
immunoprecipitation using an anti-VEGFR2 antibody. The 
immunoprecipitated proteins were then immunoblotted either with 
anti-p300 or anti-VEGFR2 antibodies. Cell lysates (30 μg) were also 
immunoblotted as a control (Input). The WCL was also incubated with 
beads conjugated with rabbit IgGs  (IgG only). 
 
Even if in a handful of reports VEGFR2 was described to shuttle from the 
cytoplasm to the nucleus (Blazquez et al, 2006; Domingues et al, 2011; 
Feng et al, 1999; Fox et al, 2004; Santos et al, 2007), we were not able to 
detect the receptor in the nucleus by neither immunofluorescence nor 
western blotting of nuclear extracts. As shown in Figure 3.4 we found 
VEGFR2 exclusively localized in the cytoplasm, both in HUVE cells stained 
with an antibody that specifically recognizes the endogenous protein 
(Figure 3.4, panel A), and in HeLa cells overexpressing the YFP-tagged 
receptor (Figure 3.4, panel B).  
The same observation was confirmed by separating nuclear and cytosolic 
fractions of EC with mild detergents, followed by immunoblotting 
analysis of protein expression. The purity of fractions was proven by 
analyzing α-tubulin and PARP as cytoplasmic and nuclear markers, 
respectively. As anticipated, VEGFR2 was present only in the cytoplasmic 
fraction, which also includes cell membranes (Figure 3.4, panel C). 
 
 
Figure 3.4. VEGFR2 subcellular localization in EC. (A) Confocal images 
of HUVE cells stained either with Toto 3 or anti VEGFR2 antibody as 
indicated above. (B) HeLa cells were transiently transfected with 
VEGFR2-YFP and stained with Toto3, followed by confocal image 
acquisition (C) HUVE cells were separated into cytoplasmic (C) and 
nuclear (N) fractions and analyzed for the distribution of the indicated 
proteins via immunoblotting. PARP-1 and Tubulin were used as nuclear 
and cytoplasmic markers, respectively. 












EC, as observed in immunofluorescence experiment. By using confocal 
microscopy, we found that endogenous p300 was preeminently 
detectable in the nucleus. At low levels, however, it was also detectable 
in the cytoplasm (Figure 3.5, panel A). 
We corroborated this immunofluorescence results by performing 
cellular fractionation of HUVE cells and subsequent analysis of protein 
localization in different fractions, as previously discussed. The vast 
majority of p300 was present in the nuclear fraction, but a small part was 
also clearly detectable in the cytosolic and membrane fraction (Figure 
3.5, panel B).  
Figure 3.5. p300 subcellular localization in EC. (A) Confocal images of 
HUVE cells stained either with Toto 3, anti-p300 or anti-CD31 antibody as 
indicated. (B) Cytoplasmic (C) and nuclear extracts (N) from HUVE cells 
were analyzed by immunoblotting with antibodies against p300. PARP-1 
and Tubulin were used as nuclear and cytoplasmic controls, respectively.  
 
 
Figure 3.6. VEGFR2 acetylation relies on p300 activity. PAE/KDR cells 
were transfected with p300, the catalytically inactive mutant p300 DY or 
an empty vector. Anti-VEGFR2 immunoprecipitates were blotted with an 
anti-acetyl lysines antibody. 
 
 
To further confirm that the enzymatic activity of p300 was directly 
required for VEGFR2 acetylation, we examined the level of receptor 
acetylation in PAE/KDR cells overexpressing the enzymatically inactive 
mutant p300 DY, carrying an inactivating, single amino-acid substitution 
(Ito et al, 2001; Sabo et al, 2008). As expected, this mutant was almost 
ineffective at inducing VEGFR2 acetylation in respect to the wt p300 
protein (Figure 3.6).  
Addionally, in HEK293T transfected with VEGFR2-Flag, the acetylation 
levels of the receptor was found to change in response to treatment 
with LysCoA, a synthetic and specific inhibitor of the p300 enzymatic 
activity (Cereseto et al, 2005; Lau et al, 2000). As it can be appreciated 
comparing lanes 1 and 2 of Figure 3.7, treatment with this inhibitor 
reduced the signal corresponding to the acetylated receptor in 
comparison to the vehicle control (Figure 3.7).  
Taken together, these findings suggest that the cytosolic fraction of 
p300 physically interacts with VEGFR2 and is the main enzyme 




Figure 3.7. LysCoA treatment diminishes VEGFR2 acetylation. 
HEK293T cells overexpressing VEGFR2 were treated with LysCoA or 
vector alone. The acetylation levels were assayed by probing the 
immunoprecipitated VEGFR2 with an anti-acetyl lysine antibody. 
 
VEGF increases VEGFR2 acetylation 
As INFα treatment partially induces CBP relocalization from the nucleus 
to the cytoplasm, thus increasing INFR type 1 acetylation (Tang et al, 
2007), we assessed the levels of acetylation of endogenous VEGFR2 in 
HUVE cells in response to VEGF stimulation. After serum starvation and 
addition of rhVEGF to the medium, VEGFR2 was immunoprecipitated 
from WCL and then probed with anti-acetyl lysine antibody. In parallel, 
the levels of receptor phosphorylation were checked using an antibody 
that specifically recognizes VEGFR2 phosphorylation on tyrosine 1173  
(human Tyr1175), an essential residue in VEGF-induced signal 
transduction (Sakurai et al, 2005). As extensively reported, 
phosphorylation of the receptor was undetectable in serum-starved cells 
in the absence of stimulation, while it rapidly peaked at 5 min after 
addition of rhVEGF, to decrease afterwards (Figure 3.8, panel A). The 
kinetics of receptor acetylation was slightly delayed compared to that of 
phosphorylation, starting to be appreciable at 5 min and peaking at 15 
min after rhVEGF addition (quantification in panel B of figure 3.8).  
 
Figure 3.8. Induction of VEGFR2 acetylation in response to VEGF 
stimulation. (A) Immunoprecipitation of VEGFR2 in HUVE cells treated 
with or without rhVEGF for the indicated time. Receptor acetylation was 
detected with an anti-acetyl lysine antibody. WCL were probed with anti-
VEGFR2, anti-phospho 1173 VEGFR2 and anti-HSC70 antibodies. (B) 
Relative quantification of VEGFR2 acetylation as fold induction over 
unstimulated receptor (mean±SEM of three different experiments). 
 
In contrast of what happens to the subcellular distribution of CBP upon 
INFα or EGF treatment (Song et al, 2011; Tang et al, 2007), we did not 
observe any changes on p300 localization in endothelial cells 
consequent to VEGF stimulation. In fact, as shown in figure 3.9, cells 
treated with the recombinant factor for different time were 
immunostained with an anti-p300 antibody and confocal microscopy 
images were acquired. In starved cells, p300 was predominantly present 
in the nucleus but also found in the cytoplasm; this distribution pattern 
remained unchanged even after prolonged treatment with VEGF. 
 
 
Figure 3.9. p300 subcellular localization upon VEGF treatment. 
Confocal images of HUVE cells treated with rhVEGF at different time 
points and stained with either Toto 3 or an anti-p300 antibody, as 
indicated above. 
On the other hand, by immunoprecipitating the receptor from HUVE cell 
WCL and probing the immunoprecipitates with an anti-p300 antibody, 
we surprisingly observed that stimulation with recombinant VEGF 
induced the association of the KAT with the receptor as early as after 5 
minutes of treatment, reaching a maximum at 15 minutes (Figure 3.10), 
thus mirroring the induction of VEGFR2 acetylation in response to VEGF 
stimulation. 
 
Figure 3.10. p300 and VEGFR2 association upon VEGF stimulation. 
HUVE cells were starved for 6 hours, and then treated with or without 
VEGF165 for the indicated time. VEGFR2 were immunoprecipitated from 
WCL, and the immunoprecipitated proteins assayed with anti-p300 and 
anti-VEGFR2 antibodies. WCL were probed with anti-VEGFR2, anti-
phospho 1173 VEGFR2 and anti-HSC70 antibodies. 
 
Thereby, analysis of the kinetics of VEGFR2 acetylation indicates that the 
receptor undergoes acetylation in a ligand-dependent manner; 
recombinant VEGF stimulation does not have an effect on p300 
subcellular distribution, whereas, in contrast, it positively affects the 
interaction between VEGFR2 and p300. 
 
HDAC5 and HDAC6 interact with and deacetylate VEGFR2 in EC 
Having shown that VEGFR2 is acetylated in EC and considering that 
acetylation is a reversible modification, we wanted to investigate which 
deacetylases recognized the receptor as a substrate.   
A first experiment was performed with the purpose to understand 
whether pharmacological inhibition had an effect on VEGFR2 acetylation 
and, should this be case, which was the class of KDACs involved in the 
deacetylation process. We found that, in HUVE cells, inhibition of class III 
KDACs (sirtuins) by nicotinamide (NAM) did not significantly affect the 
acetylation levels of endogenous VEGFR2 (Figure 3.11, panel A).  
 
Figure 3.11. Effect of specific deacetylase inhibitors on VEGFR2 
acetylation. HUVE cells WCL immunoprecipitation using an anti-VEGFR2 
antibody, and then immunoblotting with anti-acetyl lysines and anti-
VEGFR2 antibodies. In panel (A) cells were treated either with 10 μM TSA, 
20 mM NAM or DMSO as a control, whereas in panel (B) either with 10 
μM TSA, 20 μM MC1575, 10 μM MS 275 or DMSO. 
In contrast, TSA, which inhibits both class I and class II KDACs, had a 
pronounced effect, as also already shown in figure 3.1. Next we tested 
two specific inhibitors for class I and class II KDACs, namely MS275 
(entinostat) (Hu et al, 2003) and MC1575 (Mai et al, 2003; Mai et al, 2005), 
respectively.  
 
Figure 3.12. HDAC5 and HDAC6 interact with VEGFR2 in endothelial 
cells. VEGFR2 immunoprecipitates from HUVE cells contained both 
endogenous HDAC5 and HDAC6, whereas none of HDAC4, HDAC7 and 
HDAC9 co-immunprecipitated with the receptor. To discriminate among 
the different enzymes, specific antibodies were used for each member of 
class II KDACs. As controls, cell lysates (30 μg) were also immunoblotted 
in the absence of immunoprecipitation (Input), or incubated with beads 
conjugated-rabbit IgG  (IgG only). 
 
We found that the former compound did not show any detectable effect, 
while the latter (MC1575) significantly increased VEGFR2 acetylation at 
levels similar to those of TSA (Figure 3.11, panel B). 
Thus we focused on the class II enzymes. Since KDACs often physically 
interacts with their substrates, we tested binding of VEGFR2 with the 
different class II KDACs by immunoprecipitating the receptor and then 
testing for the presence of KDACs in the immunoprecipitates. These 
experiments revealed that, in HUVE cells, HDAC5 and HDAC6 interacted 
with VEGFR2, while HDAC4, HDAC7 and HDAC9 did not (Figure 3.12). 
Consistent with these findings, we observed that the overexpression of 
both HDAC5 and HDAC6 in PAE/DKR cells significantly decreased the 
levels of endogenous VEGFR2 acetylation, with HDAC5 having a more 
modest effect compared to HDAC6.  
 
 
Figure 3.13. Deacetylation of VEGFR2. PAE/KDR cells were transiently 
transfected with HDAC4, HDAC5, HDAC6 or empty vector, as indicated. 
The receptor was immunoprecipitated, and then immunoblotted with 
anti-acetyl lysines and anti-VEGFR2 antibodies. The WCL were probed 
with anti-VEGFR2, anti-Flag and anti-HSC70 antibodies. 
 
We determined the transfection efficiency by immunoblotting the WCL 
with an anti-Flag antibody. We noticed that HDAC6 was expressed at 
lower levels than HDAC5, thus reinforcing the observation that this 
enzyme was the most powerful in exerting deacetylase activity on 
VEGFR2. HDAC4 was completely ineffective, albeit being expressed at 
the same levels as HDAC5 (Figure 3.13).  
To determine the effect of class II KDACs downregulation, we established 
conditions to knock down HDAC5 and HDAC6, both individually and in 
combination; an anti-HDAC4 siRNA was used as a control for deacetylase 
specificity on VEGFR2 acetylation. siRNA-mediated knockdown of KDACs 
correlated with remarkable reduction of protein level, even below 
detectable levels via Western blot, as in the case of HDAC5 (Figure 3.14). 
HUVE cells were transiently transfected with the above indicated, 
specific siRNAs and allowed to incubate for 60 hrs. 
 
Figure 3.14. Class II KDAC redundancy. HUVE cells were transiently 
transfected with either HDAC4, HDAC5, HDAC6 or a non-targeting siRNA 
(Ctl-siRNA), as indicated. After 60 hours, cell lysates were analyzed by 
SDS-PAGE and immunoblotting for endogenous HDAC4, HDAC5 and 
HDAC6. VEGFR2 was immunoprecipitated with anti-VEGFR2 conjugated 
beads and then immunoblotted with anti-acetyl lysines and anti-VEGFR2 
antibodies. 
The cells were then harvested and immunoprecipitated with an anti-
VEGR2 antibody, followed by anti-acetyl lysine blotting analysis. In 
contrast to our expectations, siRNA-mediated downregulation of both 
HDAC5 and HDAC6 in HUVE cells did not exert any effect on VEGFR2 
acetylation, similar to the non-targeting or anti-HDAC4 siRNAs. 
Additionally, when HDAC5 and HDAC6 were simultaneously 
downregulated, there were no detectable differences in comparison 
with cells treated with a scrambled, control siRNA (Figure 3.14). Even if 
this finding seems to be apparently in conflict with the previous data 
obtained in KDACs-overexpressing cells, it simply suggests that these EC 
KDACs are redundant and thus the downregulation of one enzyme can 
be compensated by others activity. Similar findings have also been 
reported in other cell types, such as breast cancer cells, preadipocytes, 
myofibers and cardiac tissue (Chang et al, 2004; Clocchiatti et al, 2012; 
Potthoff et al, 2007; Weems & Olson, 2011). 
Finally, since we observed a transitory association between p300 and 
VEGFR2 in response to rhVEGF stimulation, we wondered whether the 
receptor association with HDAC5 and HDAC6 also followed a similar 
kinetic. Thus, we looked at the co-immunoprecipitation of the 
deacetylases with the receptor in VEGF-treated HUVE cells. Both HDAC5 
and HDAC6 were found associated with VEGFR2 in the absence of 
stimulation. Addition of the ligand, however, further promoted their 
binding, consistent with the recent findings that VEGF induces the 
phosphorylation and thus the nuclear export of several members of class 
II KDACs (Ha et al, 2008; Wang et al, 2008). In the case of HDAC5, the 
kinetics of association peaked at 15 min to rapidly decrease afterwards, 
while HDAC6 had a maximum at 5 min and then continued to remain 
associated with the receptor at later time points (figure 3.15, 
representative blot in panel A and quantifications in panel B). 
 
 
Figure 3.15. rhVEGF stimulates interaction of VEGFR2 with HDAC5 
and HDAC6. (A) HUVE cells were starved for 6 hours, and then treated 
with or without VEGF165 for the indicated time. VEGFR2 was 
immunoprecipitated from WCL, and the immunoprecipitated proteins 
then assayed with anti-HDAC5, anti-HDAC6 or anti-VEGFR2 antibodies. 
WCL were probed with anti-VEGFR2, anti-phospho 1173 VEGFR2 and anti-
HSC70 antibodies. (B) Relative quantification of HDAC5 and HDAC6 co-
immunoprecipitated with VEGFR2. Results are shown as fold induction 
over unstimulated receptor (mean±SEM of three different experiments). 
 
Collectively, these results indicate that the enzymes responsible for 
VEGFR2 deacetylation are HDAC5 and HDAC6. These two factors 
associate with the receptor in a ligand-dependent manner, resembling 
the kinetics of interaction between VEGFR2 and p300. 
Five lysines are acetylated in VEGFR2 
The mouse VEGFR2 carries a number of lysines that are well conserved in 
different species; of these, 38 are located in its intracellular portion. No 
p300 acetylation consensus site has been identified so far, hence all the 





Figure 3.16. VEGFR2-Flag silver staining. Anti-Flag 
immunoprecipitates from WCL of HEK293T transiently transfected with 
VEGFR2-Flag or empty vector were loaded on a gel and silver stained. The 
asterisks indicate the bands corresponding to fully and partially 
glycosylated VEGFR2 that underwent protemic analysis. 
 
To precisely determine which of these are the substrates for acetylation 
in vivo, we immunoprecipitated VEGFR2 from transfected HEK293T cells 
and recovered two bands from an SDS-PAGE gel, the higher of 
approximately 250 kDa and the lower of 220 kDa, corresponding to fully 
and partially glycosylated VEGFR2, respectively. Both bands were 
analyzed by MALDI-TOF mass spectrometry. One tenth of the total 
immunoprecipitate was loaded on a gel and silver stained as a control 
(Figure 3.16).  
 
 
Figure 3.17. Summary of the peptide matches for VEGFR2 in the 
MS/MS experiments. 
 
Five VEGFR2 lysines were detected as acetylated in three independent 
experiments  (for a complete list of peptide matches see table in Figure 
3.17). These residues were Lys929, Lys937, Lys939, Lys947 and Lys1053 
(corresponding to Lys931, 939, 941, 949 and 1055 of human VEGFR2 
respectively). The relative spectra are reported in Figure 3.18. 
Notably, all these residues are distributed in the cytoplasmic tail of the 
receptor, as shown in the schematic representation in Figure 3.19. The 
intracellular portion of VEGFR2 mainly consists in the kinase domain, 
which is split into two parts by the insertion of the kinase insert domain 
(KID). Four of the residues that we identified as acetylated, namely 
Lys929, Lys937, Lys939 and Lys947, form a dense cluster in the KID. They 
are located near a well-characterized tyrosine, Tyr949 (human Tyr951), 
which was shown to be phosphorylated and to mediate TSAd-dependent 






Figure 3.18. LC-MALDI tandem mass spectrometry (MS/MS) spectra 
showing acetylation of specific VEGFR2 lysine residues. Annotated 
spectra for acetylated lysine residues were produced using the GPM 
software. The acetylated residue is indicated for each spectrum and the 
b- and y- series ions are shown in blue and red, respectively. Other colors 
denote other ions such as neutral losses of water, ammonia, or internal 
fragment ions. The best scoring spectrum, based on log(e) value, is 
shown. 
 
The fifth acetylated site, Lys1053, is positioned in the activation loop of 
the receptor, within the second kinase domain. 
 
Figure 3.19. Mass spectrometry identified at least five acetylated 
lysines in VEGFR2. Schematic representation of the localization of the 











Intriguingly, this acetylated lysine is flanked by two critical 
autophosphorylation sites (Tyr1052 and Tyr1057 in the mouse 
sequence), which are required for VEGFR2 maximal kinase activity 
(Dougher & Terman, 1999).  
 
Figure 3.20. Comparison of VEGFRs sequences surrounding the 
acetylated lysines. Acetylated lysines are shown in red, reported 
phosphorylated tyrosines in green; conserved lysines are highlighted by 
a grey box. 
 
All these acetylated lysines are highly conserved between human, 
mouse and rat, as we discovered by protein alignment; moreover both 
Lys929 and Lys1053 are also maintained in mouse VEGFR1 and VEGFR3 
(Figure 3.20). 
We constructed mutants of the full-length mouse VEGFR2 carrying 
substitution of lysines with arginines, which conserve the positive 
charge, but cannot be acetylated. 
 
Figure 3.21. Construction of VEGFR2 mutants carrying Lys to Arg 
substitutions. (A) Schematic representation of Lys to Arg VEGFR2 
mutants (M1, M4, M5). Lysines mutated to arginines are indicated as “R”.  
Three mutants were generated: M1, which is mutated in the lysine 
located in the activation loop only (Lys1053Arg), M4, mutated in the four 
lysines clustered in the kinase insert domain (Lys929,937,939,947Arg), 
and M5, mutated in all the five lysines detected as acetylated (Figure 
3.21). After transfection in HEK293T cells and TSA treatment, acetylation 
of all three mutants was found significantly reduced, in particular that of 
M4 and M5 (representative experiments in Figure 3.22 panel A, and 
quantification in panel B). 
 
 
Figure 3.22. VEGFR2 mutant are less acetylated in response to TSA 
treatment (A) HEK293T cells were transfected with wt, M1, M4 or M5 
flagged VEGFR2 and treated with TSA or DMSO as a control. Flagged 
proteins were immunoprecipitated from WCL and the acetylation levels 
assayed with an anti-acetyl lysine antibody. (B) Relative quantification of 
VEGFR2 acetylation as percentage variation over wt VEGFR2 in TSA-
stimulated cells, after standardization over total VEGFR2 in each sample 
(mean±SEM). 
 
To further confirm this observation, we also tested VEGFR2 acetylation in 
vitro. We produced His-tagged recombinant proteins corresponding to 
the wild type and mutated (M1, M4 and M5) intracellular domain of 
mouse VEGFR2 (aa 805-1356). These were incubated with the 
recombinant HAT domain of p300 fused to GST, in the presence or 
absence of 14C acetyl-CoA.  
 
 
Figure 3.23. Impaired acetylation of VEGFR2 mutant in vitro. (A) His-
tagged wt VEGFR2 and its mutants M1, M4 and M5 were assayed for 
acetylation by incubation with p300-HAT in the presence or absence of 
14C acetyl-CoA; after incubation, the reaction mixture was resolved by 
SDS–PAGE and the gel exposed to a phosphoimager. Upper panels: gels 
exposed to phosphoimager. Lower panels: Coomassie-stained gels. (B) 
Relative quantification of His-VEGFR2 acetylation as density light unit 
(DLU) variation; mean±sem of three experiments. 
 
Consistent with the in vivo results, wt VEGFR2 scored clearly positive for 
acetylation, whereas the acetylation of mutants M4 and M5 appeared 
significantly impaired (representative experiment in Figure 3.23 panel 
A, and quantification in panel B). In addition to VEGFR2, the HAT domain 
of p300 was also acetylated due to the autocatalytic activity of the 
enzyme. 
These results indicate that at least five lysine residues are acetylated in 
VEGFR2. All these residues are located in the intracellular portion of the 
receptor, four in the KID and one in the activation loop, and are 
absolutely conserved among species.  
 
VEGFR2 acetylation has no effect on protein stability 
We then wanted to understand the effect of VEGFR2 acetylation on the 
receptor biology. As extensively discussed in the Chapter 1, lysine 
acetylation might have an impact on protein stability by interplaying 
with lysine ubiquitination, either hampering or favoring protein 
degradation. In any of the previous experiments, we ever observed a 
variation in VEGFR2 total protein level upon hyperacetylating 
conditions. Nevertheless, since VEGFR2 was shown to undergo 
ubiquitination (Duval et al, 2003; Murdaca et al, 2004), we precisely 
investigate the eventual role of VEGFR2 acetylation in controlling the 
receptor stability. To address this question, we compared the half-life of 
VEGFR2 in HUVE cells treated with TSA or DMSO upon de novo protein 
synthesis inhibition with cycloheximide (CHX). The protein amount was 
evaluated by immunoblotting WCL with an anti-VEGFR2 antibody, 
followed by normalization to HSC70; the quantification of protein decay 
was expressed as the percentage of reduction over cells not treated with 
CHX. As soon as after one hour of treatment with CHX, we observed an 
approximately 50% decrease of VEGFR2 protein levels, with an 
additional halving in the subsequent hour. As initially hypothesized, we 
did not notice any differences in the kinetics of degradation of VEGFR2 in 
cells treated with TSA compared to control treated cells (Figure 3.24, 
representative blot in panel A and quantification in panel B). 
 
Figure 3.24 VEGFR2 acetylation does not affect protein stability. (A) 
HUVE cells were treated with either TSA or DMSO, and CHX was added to 
the medium for the indicated times to allow protein synthesis inhibition. 
WCL were loaded onto an SDS-PAGE gel and the membrane probed with 
anti-VEGFR2 and anti-HSC70 antibodies. (B) VEGFR2 protein levels are 
quantified and plotted on the graph over time as a percentage of 
reduction over cells not treated with CHX. Squares correspond to DMSO 
treatment, whereas triangles indicate TSA treatment. (C) Same as in (A) 
in PAE cells transiently expressing either wt or M5 VEGFR2. (D) Same as in 
(B), squares correspond to wt VEGFR2, triangles indicate VEGFR2 M5. 
 
A similar experiment was also performed in PAE cells, which lack 
endogenous VEGFR2 and the Neuropilin-1 co-receptor, transfected to 
express either VEGFR2 wt or mutant M5. Also in this case, no difference 
between the two proteins was observed (Figure 3.24, representative 
blot in panel C and quantification in panel D). 
We conclude that VEGFR2 acetylation does not regulate receptor 
stability. 
Acetylation regulates VEGFR2 phosphorylation 
VEGFR2 transduces signals for endothelial cells most likely via ligand-
induced tyrosine phosphorylation followed by coupling to intracellular 
signal transducers (for a pan-phopshorylation site map see (Olsson et al, 
2006)). Since acetylation is known to modulate phosphorylation of other 
proteins (Sundaresan et al, 2011; Tang et al, 2007; Yang & Seto, 2008a) 
and given the proximity of the acetylated lysines to main VEGFR2 
autophosphorylation sites, we wondered whether acetylation of VEGFR2 
might influence its tyrosine kinase activity. To address this issue, we 
transfected PAE/KDR cells with wt p300, p300 DY or an empty plasmid, 
serum starved the cells and then stimulated them with rhVEGF. VEGFR2 
was immunoprecipitated from the WCL and, finally, probed with an anti-
total phospho-tyrosine antibody. In cells overexpressing p300, the 
magnitude of VEGF-induced receptor phosphorylation was markedly 
increased in respect to the control transfected cells. In contrast, in cells 
transfected with p300-DY, rhVEGF stimulation was almost ineffective, 
consistent with the hypo-acetylation status of the receptor and 
mirroring a potential transdominant negative effect of the p300 inactive 
mutant. In keeping with these observations, both p300 and p300-DY 
were found to co-immunoprecipitate with VEGFR2, irrespective of VEGF 
stimulation (Figure 3.25, blots in panel A and quantification of the ratios 
between phosphorylated and total receptor in panel B). 
These results strongly support the existence a crosstalk between 
acetylation and phosphorylation of VEGFR2, as the hyper-acetylation of 
the receptor upon p300 overexpression markedly enhances its 
autophosphorylation in response to ligand stimulation. 
 
 
Figure 3.25. Acetylation regulates VEGFR2 phosphorylation. (A) 
VEGFR2 was immunoprecipitated from WCL of PAE/KDR cells transfected 
with p300, p300 DY or an empty vector, with or without rhVEGF 
treatment, and then immunoblotted with an anti-phospho tyrosine 
antibody. (B) Quantification of the ratio between phosphorylated and 
total VEGFR2, shown as fold induction over untreated receptor. 
To gain insight into the role of the different lysine residues in tyrosine 
phosphorylation, we also assessed the levels of VEGF-induced 
phosphorylation of the VEGFR2 mutants in PAE cells. VEGFR2 
phosphorylation was analyzed in WCL using antibodies specific for 
phospho-Tyr1173. The mutant, non-acetylated variants of the receptor, 
especially the M4 and M5 mutants, were less phosphorylated compared 
to the wt protein (Figure 3.26, blots in panel A and quantification of the 
ratios between phosphorylated and total receptor in panel B).  
 
Figure 3.26. The non-acetylable VEGFR2 mutants show impaired 
autophosphorylation. (A) PAE cells were transfected with wt, M1, M4 or 
M5 VEGFR2 and treated with or without rhVEGF for 5 minutes. 
Phosphorylation levels of Tyr 1173 were measured and reported in (B) as 
percentage variation over wt VEGFR2 after standardization over total 
receptor. 
 
Since it is the fully glycosylated form of the receptor, expressed on the 
cell surface, that undergoes phosphorylation in response to external 
stimuli (Takahashi & Shibuya, 1997), we also performed the same 
experiment by selectively labeling the cell surface molecules with 
activated biotin, a membrane impermeant compound, followed by 
recovery of biotinylated proteins by streptavidine beads. VEGFR2 
phosphorylation was analyzed using the antibody specific for phospho-
Tyr1173 and also an antibody recognizing phospho-Tyr1052 (human 
Tyr1054), a critical autophosphorylation site located in the activation 
loop (Dougher & Terman, 1999; Dougher-Vermazen et al, 1994). We 
found that the M4 and M5 mutants showed a significant decrease in 
VEGF-induced phosphorylation on Tyr1173 (Figure 3.27, representative 
blot in panel A and quantification of the results of three independent 
experiments in panel B). As far as phosphorylation of Tyr1052 was 
concerned, instead, this was significantly reduced in mutants M1 and M5, 
while it was similar to wt in mutant M4 (Figure 3.27, blots and 
quantification in panel C and D, respectively). Of note, both M1 and M5 
carry the Lys to Arg substitution at residue 1053, which is adjacent to the 
analyzed phosphorylation site. 
Finally, we wanted to verify that the observed reduction in the 
autophosphorylation levels of the VEGFR2 mutants was not due to an 
impairment in their catalytic activity. For this purpose, the recombinant 
VEGFR2 proteins were incubated in vitro with the Poly (Glu-Tyr) peptide 
as a substrate, followed by an enzyme-linked immunosorbent assay kit to 
quantify peptide phosphorylation. The receptor kinase activity was 
comparable between wild type and M1 VEGFR2, whereas only an 
approximately 25% decrease was observed in the case of the M4 and M5 
mutants (Figure 3.28).  
 
 
Figure 3.27. The membrane-exposed fraction of VEGFR2 mutants is 
less phosphorylated in response to VEGF treatment.  PAE cells were 
transfected with wt, M1, M4 or M5 VEGFR2, starved and then treated 
with or without VEGF165 for 5 minutes. Phosphorylation levels of Tyr 1173 
(A) and Tyr 1052 (C) were assessed after cell surface biotinylation with 
thiol-cleavable Sulfo-NHS-SS-Biotin. Relative quantification of ratio 
percentage of VEGFR2 phosphorylation in Tyrosine 1173 (B) and 1052 (D) 
upon total VEGFR2 are shown on the right of the panels.  
This finding rules out that the major impairment observed for the 
mutant receptor phosphorylation might be consequent to an 
intrinsically decreased kinase activity. This observations, in combination 
with our previous findings, indicate that acetylation of the receptor by 
p300 markedly enhances its autophosphorylation in response to ligand 
stimulation. Moreover, mutation of the acetylated residues significantly 
impairs ligand-induced VEGFR2 autophosphorylation at Tyr1052 and 




Figure 3.28. Mutation of the acetylated lysines in VEGFR2 does not 
impair receptor kinase activity. His-tagged VEGFR2, either wt or 
mutants, was incubated with Poly(Glu-Tyr) peptide in the presence or 
absence of ATP, and substrate phosphorylation was monitored by 
enzyme-linked immunosorbent assay. Data are represented as 
absorbance values at 450 nM (mean±SEM of three independent 
experiments). Lower panel: Coomassie-stained gel used to verify the 
quantity of protein loaded for each reaction. 
 
Structural modeling of the VEGFR2 activation loop  
Next we wanted to get structural insights into the role of Lys1053 
acetylation in the conformation of the activation loop. An exhaustive 
search in the Protein Data Bank (www.pdb.org) revealed that, among the 
38 structures reported for VEGFR2 in complex with different inhibitors, 
only 7 contain the complete structure of the activation loop in its 
unphosphorylated form.  
 
Figure 3.29. X-ray structures of VEGFR2 in complex with different 
inhibitors. The structures contain the complete receptor activation loop 
in its unphosphorylated form (PDB ids: 4AGD, 4AGC, 4AG8, 3U6J, 3VHK, 
4ASE and 3VNT). The protein segments, before and after the kinase 
activation loop, are represented as pale blue and orange cartoons, 
respectively, whereas residues pY1052, Lys1053 and pY1057 are shown 
in sticks.  
 
Notably, in all these X-ray structures (PDB ids: 4AGD, 4AGC, 4AG8, 3U6J, 
3VHK, 4ASE and 3VNT), Lys1053 is completely exposed to the solvent 
(Figure 3.29) and both, or at least one, of the tyrosines present in the 
activation loop (Tyr1052 and Tyr1057) are completely buried. 
Therefore, we sought to perform molecular dynamics simulations 
starting from the structure of VEGFR2 phosphorylated at Tyr1052 and 
Tyr1057 and in complex with a benzimidazole inhibitor (PDB id: 2OH4, 
Figure 3.30, panel A) (Hasegawa et al, 2007). Simulations were performed 
removing the inhibitor from the following systems: wt VEGFR2 kinase 
domain phosphorylated at Tyr1052 and 1057 (Figure 3.30, panel B); wt 
VEGFR2 kinase domain unphosphorylated (Figure 3.30, panel C); wt 
VEGFR2 kinase domain phosphorylated at Tyr1052, 1057 and acetylated 
at Lys1053 (Figure 3.30, panel D); wt VEGFR2 kinase domain 
unphosphorylated and acetylated at Lys1053 (Figure 3.30, panel E); and 
VEGFR2 kinase domain Lys1053Arg mutant (Figure 3.30, panel F). 
Analysis of these computational models revealed that the removal of the 
phosphoryl groups from Tyr1052 and Tyr1057 resulted in a reduction of 
the Solvent Accessible Surface (SAS) of the phosphorylation motif, most 
likely due to a reduction of the electrostatic repulsion (Figure 3.31).  
 
Figure 3.30. Structural modeling of acetylated VEGFR2. (A) X-ray 
structure of VEGFR2 (PDB code 2OH4). The color scheme is the same as in 
figure 3.25. The benzimidazole inhibitor is shown in semitransparent 
space filling representation. (B to F) Final structures of the simulations of 
different VEGFR2 systems are shown. (B) VEGFR2 phosphorylated at 
Y1052 and Y1057. (C) Unphosphorylated receptor. The circular section 
marks the activation loop. (D) VEGFR2 phosphorylated at Y1052, 1057 
and acetylated at Lys1053. (E) VEGFR2 unphosphorylated and acetylated 
at Lys1053. The circular section marks the activation loop. (F) VEGFR2 
mutant Lys1053R.  
This result is in agreement with the more compact conformation 
obtained for the activation loop in its unphosphorylated form (cf., for 
instance, ref. (Oguro et al, 2010)) in which lysine 1053 is partially buried 
inside the middle of the activation loop, flanked by Tyr1052 and Tyr1057 
(Figure 3.30, panel A and C). Lysine acetylation of the unphosphorylated 
protein resulted in a more exposed conformation of the activation loop, 
in which tyrosine residues were uncovered and thus accessible for 
phosphorylation (Figure 3.30, panel E).  
 
Figure 3.31. Activation loop solvent accessible surface. Time 
evolution of the solvent accessible surface area (SAS) calculated on the 
activation loop for the different systems that were simulated. 
 
On the contrary, acetylation at Lys1053 of the phosphorylated protein 
did not affect significantly the structure (Figure 3.30, panel B and D and 
Figure 3.31). Furthermore, mutation of Lys1053 into arginine generated 
a more compact conformation, comparable to that of the unmodified 
protein (Figure 3.30, panel F and A); this simulation resulted in the least 
flexible system, in which the entire activation loop was stabilized by the 
establishment of a network of hydrogen bonds (Figure 3.30, panel F and 
magnification in Figure 3.32). This conformation showed a clear 
impairment in the exposure of the tyrosines, which could thus be 
phosphorylated less favorably.  
Taken together, these results provide a structural model to explain the 
increased levels of VEGF-induced VEGFR2 phosphorylation imparted by 
acetylation by enzymatically active p300 and, more specifically, the 
remarkable reduced levels of Tyr1052 phosphorylation in the 
Lys1053Arg mutant.  
 
Figure 3.32. Magnification of the activation loop in Lys1053R 
VEGFR2. The activation loop is shown from a different orientation to 
highlight the network of hydrogen bonds established by R1053, shown 
as dashed yellow lines.  
 
 
Acetylation prevents receptor desensitization 
Different Receptor Tyrosine Kinases (RTKs), including VEGFR2, can 
undergo receptor desensitization as a means of rapid dephosphorylation 
soon after activation (Ewan et al, 2006; Lanahan et al, 2010; Lemmon & 
Schlessinger, 2010; Nakamura et al, 2008).  
Figure 3.33. Acetylation regulates VEGFR2 desensitization. (A) 
PAE/KDR cells were treated or not with TSA and stimulated for different 
time points with rhVEGF. WCL were probed with antibodies against 
phospho-Tyr1052, phospho-Tyr1173, VEGFR2 and HSC70. (B) Relative 
quantifications of VEGFR2 phosphorylation at Tyrosine 1173 and 1052 
are shown after standardization over total VEGFR2 and expressed as fold 
over untreated receptor (mean±SEM of three indepedent experiments). 
 Given the striking role of acetylation in enhancing VEGFR2 
phosphorylation, we wanted to explore the possible role of acetylation 
in modifying the kinetics of VEGFR2 phosphorylation after VEGF-induced 
activation.  
                 
Figure 3.34. VEGF-induced signal transduction upon VEGFR2 
hyperacetylation. (A) PAE/KDR cells were treated or not with TSA and 
stimulated for different time points with rhVEGF to induce receptor 
desensitization. WCL were immunoblotted with anti-phospho ERK 1/2, 
anti-ERK 1/2 and anti-HSC70. (B) Relative quantification of the ratio 
between ERK 1/2 phosphorylated at threonine 202 and tyrosine 204 and 
total ERK 1/2. The results are shown as fold induction over unstimulated 
cells (mean±SEM of three independent experiments). 
 
Serum starved PAE/KDR cells were treated with rhVEGF and collected at 
different times after stimulation, as indicated; the levels of VEGR2 
phosphorylation on Tyr1173 and Tyr1052 were analyzed by WCL western 
blotting comparing DMSO control conditions and TSA treatment, which 
preserves VEGFR2 acetylation. In control conditions, the levels of 
phosphorylated VEGFR2 at both residues peaked at 5 min to sharply 
decrease at 15 min and remain very low in the subsequent hour. In 
contrast, in the TSA-treated cells, phosphorylation was remarkably 
higher after 5 min of stimulation and, most notably, was maintained over 
time (Figure 3.33, representative blots in panel A).  
Figure 3.36. The non-acetylable M5 VEGFR2 mutant does not 
respond to prolonged VEGF treatment. (A) PAE cells were transfected 
with wt or M5 VEGFR2 and treated with rhVEGF for different time points. 
VEGFR2 phosphorylation levels of Tyr 1173 were quantified and reported 
in (B) as fold over untreated receptor (mean±SEM of three different 
experiments), after standardization over total VEGFR2. 
 
The levels of phosphorylated VEGFR2 over total VEGFR2 was quantified 
and plotted on the graph as fold over untreated receptor (Figure 3.33, 
panel B). The increased levels of phosphorylated VEGFR2 in TSA-treated 
cells were paralleled by increased phosphorylation of Erk1/2, a pivotal 
downstream effector of the receptor (Figure 3.34, representative blots 
in panel A and quantification in panel B). 
The same experiment was performed comparing the kinetics of 
activation of wt VEGFR2 and the non-acetylable mutant M5. Consistent 
with the previous observations, this mutant was remarkably impaired in 
VEGF-induced phosphorylation on Tyr1173 (Figure 3.36, panel A for 
representative blots and panel B for quantification). 
Together these data support the conclusion that VEGFR2 acetylation 
contrasts receptor desensitization, counteracting its dephosphorylation, 
without any detectable effect in the process of receptor 
downregulation. 
 
Acetylation enhances VEGFR2 function 
To further elucidate the functional significance of acetylation in VEGFR2 
activity, we monitored the efficiency of wound healing of PAE cells 
transiently transfected with VEGFR2 wt or mutant M5.  
 
Figure 3.37. Wound size analysis. PAE cells transiently expressing 
VEGFR2 wt were imaged by phase contrast microscopy (a); the calculated 




In this assay, cell motility depends on VEGF stimulation. The cells were 
grown to 100% confluence, serum starved and treated with thymidine 
to block proliferation. We then mechanically created a cell free zone in 
the monolayer and kept the cells in the absence of serum or in the 
presence of rhVEGF for 24 hrs.  
 
Figure 3.38. Expression of the M5 VEGFR2 mutant in PAE cells affects 
their response to migratory stimuli. (A) The migratory capability of PAE 
cells transiently expressing either wt or M5 VEGFR2 was measured by a 
wound healing assay, in the presence or absence of rhVEGF. (B) 
Quantification of cell migration area into the wound area. The extent of 
wound closure quantified by measuring the wound area at 24 hours 
compared to time 0. * indicates P<0.05. (C) After 24 h of stimulation with 
rhVEGF, PAE cells subjected to wound healing assay were collected and 
the levels of expressing proteins were analyzed by western blotting. 
Phase-contrast images were taken immediately after scratch (t=0) and 
24 hours after rhVEGF stimulation (t=24) and the migration rate of the 
endothelial cells was determined after quantification of the wound size 
at fixed time points  (Figure 3.37). 
We found that, in wt VEGFR2-expressing cells, VEGF treatment for 24 
hours clearly induced cell motility to fill the wounded monolayer; on the 
contrary, this effect was markedly impaired in cells expressing mutant 
M5, which failed to respond to VEGF stimulation (Figure 3.38, 
representative images in panel A and quantification in panel B). Wild 
type VEGFR2 and mutant M5 were equally expressed in the PAE cells 
(Figure 3.38, panel C). 
Thus, VEGFR2 acetylation enhances the receptor activity in inducing 










VEGFR2 is modified by acetylation 
Over the last few years, a large body of evidence has shown that post-
translational modification by acetylation has a major role in the 
regulation of protein function. Most notably, protein acetylation is not 
confined to the nuclear compartment but also occurs for cytoplasmic 
proteins, such as α-tubulin, cortactin and Hsp90 (Bali et al, 2005; 
Matsuyama et al, 2002; Zhang et al, 2007). Information is more scant as far 
as membrane-associated factors are concerned. The type I interferon 
receptor (IFNαR2), together with interferon regulatory factor 9 (IRF9) 
and the activators of transcription STAT1 and STAT2, were all found to be 
acetylated by CBP (Tang et al, 2007), implying a role for acetylation in the 
control of cytokine receptor signal transduction. Post-translational 
modification by acetylation was also suggested to regulate clathrin-
mediated endocytosis (Goh et al, 2010) and activity (Song et al, 2011) of 
the epidermal growth factor receptor (EGFR). Moreover, the acetylation 
of the Insulin-like Growth Factor 1 (IGF-1) receptor has been detected 
during a mass spectrometry survey (Choudhary et al, 2009). 
We provide evidence that VEGFR2 is acetylated in vivo and that receptor 
acetylation has an important role in regulating VEGF-induced receptor 
phosphorylation. Given the essential function of VEGFR2 in vascular 
development, it does not appear surprising that the functionality of this 
receptor is finely tuned at the level of gene expression regulation 
(Olszewska-Pazdrak et al, 2009; Plate et al, 1993), as well as through 
intracellular trafficking (Lampugnani et al, 2006; Lanahan et al, 2010; 
Manickam et al, 2011; Mukherjee et al, 2006; Sawamiphak et al, 2010) 
and post-translational modifications of the mature protein (Duval et al, 
2003; Koch et al, 2011; Murdaca et al, 2004; Takahashi & Shibuya, 1997). 
Thereby, the acetylation of VEGFR2 enlightens another crucial 
mechanism that dynamically modulates receptor activity. More 
generally, our findings, together with those regarding EGFR, as well as 
IFNαR2 and IGF-1, strengthen the concept that protein acetylation 
represents a novel mechanism of regulation of receptor function which 
might broadly applies to RTK family members. 
 
Conserved acetylated residues in VEGFR2 intracellular domain 
By exploiting proteomic analysis, we found several acetylation sites in 
murine VEGFR2, mainly located in the intracellular part of the receptor. 
In particular, the peptides encompassing Lys929, Lys937, Lys939, Lys947 
and Lys1053 were identified several times in three independent 
experiments. Notably, all this residues are conserved in mouse, human 
and rat, thus suggesting their relevance in regulating receptor function. 
In addition, lysines 929 and 1053 are also conserved in VEGFR1 and 
VEGFR3 of mouse origin. In agreement, we found acetylated VEGFR2 of 
both mouse and human origin; moreover, the receptor acetylation is not 
cell type specific as well, since we were able to reproduce our findings in 
different cell lines. 
Lysines at positions 929 to 947 form a dense cluster in the KID. 
Interestingly, acetylation of lysine residue groups has also been found to 
form positive charged patches in other proteins, such as p53, cortactin 
and EGFR (Goh et al, 2010; Kawaguchi et al, 2006; Zhang et al, 2007); of 
notice, the enzymatic activity of p300 is tightly regulated by the overall 
acetylation of 13 lysines located in the acetyltransferase activation loop 
(Thompson et al, 2004). Importantly, in VEGFR2 this cluster of residues is 
adjacent to tyrosine 949, an important autophosphorylation site, known 
to mediate TSAd-dependent cell signaling (Matsumoto et al, 2005).  
In contrast to the 929-947 lysine cluster, lysine 1053 is not surrounded 
by other acetylated lysines. Instead, this lysine is located in the middle of 
the VEGFR2 activation loop, near two critical autophosphorylation sites 
(Tyr 1052 and Tyr 1057) (Dougher & Terman, 1999). It is compelling to 
note that the regions surrounding VEGFR2 acetylated lysines appear to 
conform to the general residue preferences in the proximity of 
acetylated sites, as detected by various computational analysis, 
according to which acetylation preferentially occurs in regions with 
ordered secondary structure, with a widespread preference for lysine-
rich regions containing a residue that can be phosphorylated and with a 
particular predilection for negative charge residues in the immediate 
surrounding of the modified site (Basu et al, 2009; Choudhary et al, 2009; 
Gnad et al, 2010; Schwartz et al, 2009). 
 
Crosstalk between acetylation and phosphorylation 
Protein acetylation has been frequently linked to other PTMs. A growing 
body of evidence supports the existence of a crosstalk among the various 
PTMs, a sort of “protein modification code” responsible for the final 
regulation of protein function (Hunter, 2007; Yang & Seto, 2008a).  
Lysine acetylation has an important regulatory potential in the control of 
protein stability by mingling with protein ubiquitination (Caron et al, 
2005; Sadoul et al, 2010). Nevertheless, even if VEGFR2 has been found 
subjected to ubiquitin-dependent degradation (Duval et al, 2003; Ewan 
et al, 2006), we were not able to observe any differences between the 
half-life of either mutant M5 VEGFR2 or TSA-induced hyperacetylated 
receptor compared to the wt, not-treated protein. Thereby, since we 
provide evidence that it does not exist any correlation between VEGFR2 
acetylation and stability, the possible impact of acetylation on receptor 
function might reside elsewhere.   
Interestingly, many examples have been already reported stating that 
acetylation act in concert with phosphorylation to regulate protein 
functions. Most notably, both in the case of EGFR and IFNαR2, lysine 
acetylation has already been shown to regulate receptor function in 
coordination with phosphorylation (Song et al, 2011; Tang et al, 2007). 
Our work indeed shows that acetylation of VEGFR2 was effective at 
inducing an increase in the overall phosphorylation level of the receptor 
in response to VEGF stimulation. In particular, computational modeling 
of the VEGFR2 activation loop indicates that acetylation of lysine 1053, 
by quenching the positive charge of the residue, aids in the transition of 
the activation loop towards a more open state, in which the two tyrosine 
residues 1052 and 1057 are better exposed on the surface of the protein 
and become accessible for phosphorylation. Mutation of lysine 1053 into 
arginine, instead, generated a less flexible system, in which the entire 
activation loop was partially buried and stabilized by a network of 
hydrogen bonds. Our structural modeling is corroborated by the 
observation that the non-acetylable VEGFR2 mutants showed impaired 
auto-phosphorylation capability. More specifically, the lack of acetylation 
at lysine 1053 correlated with a decrement in the phosphorylation at 
tyrosine 1052, an effect that our in vitro phosphorylation studies showed 
to be not consequent to an intrinsic loss of receptor tyrosine kinase 
activity in the absence of ligand following residue substitution. Thus, 
VEGFR2 joins the growing list of proteins in which lysine acetylation 
regulates enzymatic activity, including Cdk2, Cdk9 and p38 (Mateo et al, 
2009; Pillai et al, 2011; Sabo et al, 2008). 
The hypothesis that residue charge influences receptor 
autophosphorylation in the activation loop has been already put forward 
by mutational data on both VEGFR1 and VEGFR2, which indicate that 
mutation of an invariable, negatively charged aspartic acid to non-polar 
asparagine at position 1054 lowers the autophosphorylation of 
activation loop tyrosines 1052 and 1057 (Meyer et al, 2006). The 
presence of this same asparagine in VEGFR1 might explain the poor 
autophosphorylation and signal transduction activity of this receptor in 
endothelial cells (Meyer et al, 2006). In this respect, it is worth 
mentioning that VEGFR1 was also found modified by acetylation in a 
recent mass spectrometry survey aimed at identifying new acetylated 
proteins (Chen et al, 2012). It will be of interest to understand to what 
extent VEGFR1 acetylation is also involved in the regulation of this 
receptor.  
The acetylation occurring in lysine-rich region has been widely 
hypothesized to affect protein function most likely by leading to protein 
conformational shift, as in the case of p300 and p53 (Arif et al, 2007; Black 
et al, 2006; Laptenko & Prives, 2006). Unfortunately, we were not able to 
provide a molecular modeling of the region surrounding the 929-947 
lysine cluster, since so far the high electrostatic charge and 
hydrophilicity of the KID sequence did not render the crystallization of 
the VEGFR2 catalytic domain with the entire KID sequence possible 
(Hasegawa et al, 2007; McTigue et al, 1999). Nevertheless, we could not 
exclude that a mechanism of acetylation-induced conformational 
change, similar to that observed in the VEGFR2 activation loop, might 
affect several VEGFR2 catalytic residues, in particular tyrosine 1173. 
 
Molecular players in VEGFR2 reversible acetylation 
Our experiments reveal that, among the KAT enzymes analyzed, p300 is 
responsible for VEGFR2 acetylation in both endothelial and non-
endothelial cells. Besides its well established function as a 
transcriptional co-activator in the nucleus, p300 is known to shuttle in 
and out of the nucleus and to act also in the cytoplasm (Shi et al, 2009; 
Tang et al, 2007). We found p300 partially localized in the cytoplasm in 
HUVE cells; most likely, it is the cytosolic fraction of the KAT the one 
responsible for the acetylation of VEGFR2. Previous work indicates that 
the depletion of p300 significantly reduces angiogenic tubule formation 
(Pillai et al, 2010). This report is fully consistent with our findings, in 
particular with the experiments showing that the receptor mutated in 
the lysines that undergo p300-mediated acetylation has impaired ability 
to induce endothelial cells migration in response to VEGF. Thus, in 
addition to enhancing VEGFR2 expression by acting at the level of the 
gene promoter (Pillai et al, 2010), p300 has the additional role of 
promoting receptor function by acetylating the mature protein. 
Increasing evidence indicates the contribution of class IIa KDACs, such as 
HDAC5, HDAC6 and HDAC7, to the angiogenic function of endothelial 
cells. Both HDAC5 and HDAC7 are negative regulator of angiogenesis, by 
having an impact on transcriptional regulation of gene expression in EC 
(Urbich et al, 2009; Wang et al, 2008). On the contrary, HDAC6 has been 
shown to promote angiogenesis in vitro and in vivo by deacetylating the 
cytoplasmic actin-remodeling protein cortactin in endothelial cells, 
thereby regulating endothelial cell migration and sprouting (Kaluza et 
al, 2011). We found that specific inhibition of class II KDACs markedly 
increased the level of acetylation of VEGFR2, with both HDAC5 and 
HDAC6 being able to co-immunoprecipate with and deacetylate VEGFR2. 
In addition, the two KDACs interacted with the receptor in a VEGF-
dependent manner, in agreement with recent findings showing that 
treatment with VEGF promotes nuclear export of class II KDACs in 
endothelial cells (Ha et al, 2008; Wang et al, 2008). 
 
VEGF induces VEGFR2 acetylation 
Similar to acetylation of IFNαR2, which was demonstrated to be 
dependent on INFα stimulation (Tang et al, 2007), we found that in HUVE 
cells VEGFR2 acetylation was induced by VEGF treatment. In contrast to 
what happens to the CBP subcellular distribution upon INFα or EGF 
treatment (Song et al, 2011; Tang et al, 2007), we did not observe any 
variation on p300 localization in EC consequent to VEGF stimulation. 
Nevertheless, the formation of a complex between VEGFR2 and p300 was 
VEGF-dependent, and correlated with the increment of receptor 
acetylation, reaching the maximum after 15 minutes of growth factor 
stimulation. At this time point, the activity of the deacetylases associated 
with the receptor prevails, with the subsequent, progressive 
deacetylation of the receptor. An interplay between p300 and HDAC6 is 
already known to exist in other settings. In particular, p300 has been 
involved in the attenuation of HDAC6 activity, by directly interacting 
with and acetylating the class II histone deacetylase (Han et al, 2009; Liu 
et al, 2012). Additionally, HDAC6 has been shown to hamper the 
interaction between p53 and p300, interfering with p300-mediated p53 
acetylation (Ding et al, 2013). Thus, we could not rule out a further 
synergism between p300 and HDAC6 in regulating VEGFR2 acetylation, 
by indirectly affecting their activity one another. Indeed, VEGF might 
play a pivotal role in keeping the balance between the action of the 
abovementioned KAT and KDACs. 
 
VEGFR2 acetylation prompts receptor activity 
Different RTKs, including VEGFR2, undergo desensitization upon 
prolonged ligand stimulation, involving dephosphorylation, ligand-
induced removal from the plasma membrane by endocytosis and 
subsequent lysosomal proteolysis of both ligand and receptor molecules 
(Duval et al, 2003; Ewan et al, 2006; Gampel et al, 2006; Singh et al, 2005; 
Singh et al, 2007). Consistent with the previous data regarding the 
kinetics of p300 and HDAC5 and -6 association with VEGFR2, the 
inhibition of KDAC activity preserves receptor phosphorylation over 
time after ligand stimulation and maintains its capacity to transduce 
intracellular signals for longer times in endothelial cells. In contrast, the 
mutant M5 failed to respond to VEGF stimuli, thus confirming all the 
previous observations. Therefore, it is likely that under VEGF-stimulating 
conditions, receptor acetylation contributes to the maintenance of 
VEGFR2 phosphorylation and activation. Consistently, the impaired 
receptor activation of the non-acetylable M5 VEGFR2 was reflected by 
the mutant incapability to induce EC migration in response to VEGF 
stimuli. 
Taken together, our findings support the conclusion that VEGFR2 
acetylation favors and sustains receptor phosphorylation and activation 
in endothelial cells, and reinforces the concept that a strict crosstalk 
exists between post-translational modification by acetylation and other 
PTMs (Hunter, 2007; Yang & Seto, 2008a).  
 
Protein acetylation in angiogenesis 
Protein acetylation exerts a pleiotropic role in the control of EC function, 
having an impact on both gene expression and regulation of non-histone 
protein.  
The effect of KDAC activity in the activation of VEGF-responsive genes in 
EC is undoubted.  As already mentioned, VEGF directly controls the 
nuclear export of class II KDACs, therefore promoting angiogenesis 
through activation of several VEGF-responsive genes (Wang et al, 2008; 
Ha et al, 2008;Urbich et al, 2009). Consistently, the inhibition of KDACs 
activity by TSA has been found to decrease angiogenesis in vitro and in 
vivo, an effect that appears to be directly dependent on the negative 
modulation of VEGFR1, VEGFR2 and NP1 gene expression (Deroanne et al, 
2002). In addition, the upregulation of HDAC1 by hypoxia leads to the 
induction of angiogenesis by increasing the expression of both VEGF and 
HIF-1α, a transcription factor pivotal in the angiogenic process (Kim et al, 
2001). Of notice, under hypoxic condition, HDAC7 forms a complex in the 
nucleus with p300 and HIF-1α, finally potentiating HIF-1α transcriptional 
activity (Kato et al, 2004).  
The acetylation in EC of many non-histone proteins has also been 
reported to markedly influence the angiogenic process. Besides 
cytoplasmic cortactin (Kaluza et al, 2011; Zhang et al, 2007), the 
transmembrane protein Notch-1 is acetylated as well, a modification 
reversed by the deacetylase SIRT1. Notch-1 acetylation alters its 
intracellular domain turnover, thus increasing its stability and the 
duration of Notch signaling in EC (Guarani et al, 2011). HIF-1α itself has 
been found modified by acetylation, but the functional consequence of 
this modification is still under debate, since HDAC6 and HDAC4 
inhibition has been demonstrated to target the transcription factor for 
proteasomal degradation (Geng et al, 2011; Jeong et al, 2002; Qian et al, 
2006), whereas the acetylation at lysine 674, reversed by SIRT1, seems to 
be required for its transcriptional activation (Lim et al, 2011). 
 
Concluding remarks 
Being the KDAC expression frequently altered in solid tumor 
malignancies and given their global effect on histone modulation, it is 
not surprising that several KDAC inhibitors (KDACi) have recently 
emerged as potential therapeutic agents for the treatment of different 
human cancers (Ellis et al, 2009). The apparent contradiction between 
the use of KDACi for tumor angiogenesis inhibition and our novel finding 
linking VEGFR2 hyperacetylation with increased receptor activation 
might be partially explained by the fact that prolonged deacetylases 
inhibition might have a major impact on genome expression, rather than 
fine tuning VEGFR2 activity.  
Notably, a lack of therapeutic effects was however observed when a 
KDACi was used as a single therapeutic agent, while the combined 
treatment with other agents, such as Tyrosine Kinase Inhibitors (TKI), 
appeared to increase KDACi anti-tumor activity (Qiu et al, 2013; Thurn et 
al, 2011). In this respect, being also the phosphorylation of EGFR 
enhanced upon TSA treatment in cancer cells (Song et al, 2011; Zhou et 
al, 2006), a challenging issue would be to understand whether the 
acetylation-dependent misregulated activity of both VEGFR2 and EGFR 
might be responsible for the KDACi monotherapy failure in cancer 
therapy. 
More generally, it remains a matter for interesting future investigation 
whether this novel mechanism of regulation of receptor function also 
applies to other VEGFRs and RTKs. In particular, the recent implication of 
KDACi in the control of cardiac hypertrophy (McKinsey, 2011) is worth of 
note. Preclinical results have reported a profound efficacy of these drugs 
in suppressing chronic cardiac hypertrophy and pathological cardiac 
fibrosis (Cao et al, 2011; Kee et al, 2006; Kong et al, 2006b; Liu et al, 
2008a). The actual mechanisms by which KDACi exert their function in 
the cardiac tissue still need to be fully elucidated. Current interpretation 
of these findings implies a combination of deacetylase activity on both 
histone and non-histone targets, such as the sarcomere components 
(Gupta et al, 2008). Given the key role of VEGFR1 in cardiac function, it 
appears tempting to speculate that the activity of VEGFR1 might also be 
involved in the protective effects of KDACi. 
Despite all the efforts that have been invested over the last years to 
unravel the complexity of the acetylome, we are still far from entirely 
clarifying the many roles of protein acetylation in the control of cellular 
function as well as its implication in the onset of disease. The 
identification of new acetylated protein targets offers indeed the 
possibility to focus on precise biochemical KDAC targets and to elucidate 
their mechanism of action. With this knowledge, more specific drugs 
could be developed, and, thereby, more suitable therapeutic treatments 
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